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1. INTRODUCTION 
Already more than a century ago two eminent scientists, Thomas Henry Huxley 
and Paul Ehrlich, envisioned a future when doctors could treat diseases by using 
a “very cunningly contrived torpedo” (Huxley, 1881), or “Zauberkugeln” (“ma-
gic bullets”) (Ehrlich, 1908) to specifically strike diseased tissues while sparing 
healthy organs. Thanks to advances in the field of drug delivery systems (DDS) 
in the last decades, this vision is becoming a reality (Allen, Cullis, 2004, Shi et 
al., 2017). Recent progress in improving DDS has nothing to do with magic, but 
with taking advantage of the pathophysiological changes in the microenviron-
ment of the diseased tissues.  
Cancer stands out as the disease most likely to benefit from precision drug 
delivery. Conventional anti-cancer therapies rely on the use of low molecular 
weight drugs that preferentially kill rapidly proliferating tumor cells rather than 
normal cells. However, existing anti-cancer drugs show poor cancer selectivity 
and limited penetration of malignant tissue leading to low drug concentration in 
the tumors and limited therapeutic efficacy (Shi et al., 2017). It has been 
demonstrated with PET biodistribution studies using labeled drugs that small-
molecule therapeutic agents do not preferentially localize at neoplastic sites 
(van der Veldt et al., 2010, van der Veldt et al., 2011). For therapeutic effect, 
large doses of a drug must be used, which causes toxicities in non-malignant 
cells and side effects. The development of precision anti-cancer drugs ables to 
distinguish normal and cancer cells and is one of the main goals of modern anti-
cancer research. Malignant tissues have features that can be targeted in order to 
increase accumulation of drugs at the tumor site and their therapeutic efficacy. 
First, enhanced permeability and retention (EPR) effect, caused by increased 
leakiness of tumor blood vessels, results in passive accumulation of drug in the 
tumor tissue (Matsumura, Maeda, 1986); second, cancer-associated signature 
molecules on the surface of tumor neovessels, tumor cells, and tumor-associated 
cells can be targeted with affinity ligands such as peptides. Affinity-based drug 
delivery is referred to as “synaphic” targeting; it is also referred to as patho-
tropic or active targeting (Ruoslahti, Bhatia & Sailor, 2010). 
Primary cancers of gastrointestinal and gynecological origin often dissemi-
nate locoregionally in the peritoneal cavity to give a rise to a serious condition 
known as peritoneal carcinomatosis (PC). Intraperitoneal (IP) cancers are 
treated with a combination of surgical removal and adjuvant chemotherapy. 
However, due to micrometastases left behind during surgery and inefficient 
systemic chemotherapy, many patients experience a relapse. IP chemotherapy – 
administration of anticancer drugs to the peritoneal cavity – is used to decrease 
systemic exposure and to achieve high peritoneal concentration of cytotoxic 
drugs without relying on the blood supply. The efficacy of IP chemotherapy is 
decreased by the rapid escape of conventional non-targeted chemotherapeutics 
from the peritoneal space into systemic circulation, especially for smaller mole-
cular weight agents. Novel strategies such as the development of precision 
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nanomedicines to specifically target cancerous lesions and the development of 
drugs/nanoparticles with extended residence time in the IP cavity may help to 
improve clinical management of PC. 
Tumor penetrating peptides (TPP) are a novel class of tumor targeting pepti-
des that can be used to deliver diagnostic and therapeutic payloads deep into 
malignant tissue parenchyma. After selective recruitment to tumor-associated 
receptors on tumor endothelial cells, TPP are proteolytically processed to trig-
ger a secondary interaction with cell- and tissue penetration receptor NRP-1 that 
activates a pathway of active transport into extravascular tumor parenchyma. 
Due to multistep recruitment and activation pathway, the TPP are highly tumor 
specific. TPP platform provides a solution to the problem of poor penetration of 
drugs, imaging agents, and nanoparticles into tumors. 
The goal of this thesis was to perform preclinical studies to explore applica-
tions of peptide-mediated targeting of nanocarriers for precision delivery to IP 
tumors. We used different classes of nanoparticles (NP) based on polymers, iron 
oxide and metallic silver – each with unique advantages, such as high drug 
loading capacity and ability to exit endosomes upon cellular internalization 
(polymersomes), possession of inherent contrast for MR imaging (iron oxide 
NPs), and sensitivity to etching solution that allows distinguishing extracellular 
and intracellular nanoparticles (silver NPs). Whereas these nanoscale platforms 
have been reported to be compatible with systemic delivery of payloads (Toome 
et al., 2017, Sharma et al., 2017, Pang et al., 2010), none of the nanoplatforms 
had been evaluated for IP delivery to peritoneal tumors at the beginning of our 
series of studies. Therefore, we performed a systematic assessment and pre-
clinical development of nanocarriers for IP PC targeting. First, we conjugated 
different TPP to the NPs and tested interactions of peptide-NPs with cultured 
malignant cells in vitro. Second, we studied biodistribution and tumor tropism 
of the IP-administered TPP-NP in a panel of clinically relevant mouse models 
of PC. Finally, we studied the preclinical efficacy of TPP-NPs during experi-
mental intraperitoneal tumor therapy. 
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2. REVIEW OF THE LITERATURE 
2.1. Intraperitoneal (IP) carcinomatosis:  
challenge and current treatment options 
Gastrointestinal and gynecological malignancies frequently metastasize in the 
peritoneal cavity and lead to severe complications such as bowel obstruction 
and the formation of ascites. At the time of diagnosis peritoneal dissemination 
of tumors is present in about 50% of gastric, 30% of ovarian and 40% of colo-
rectal cancer patients (Goodman et al., 2016). PC has no clear clinical symp-
toms and is typically detected at a late stage when a large number of tumor 
micronodules are present over the peritoneal membranes (Sadeghi et al., 2000). 
PC patients undergo aggressive treatment through combination of surgical re-
section and/or chemotherapy (Bajaj, Yeo, 2010). However, PC is almost im-
possible to cure as complete surgical removal of all tumor microfoci is not pos-
sible and systemic chemotherapy has limited efficacy due to the poor vascu-
larization of tumor nodules and the presence of the peritoneum-plasma barrier 
which prevents effective drug delivery from systemic circulation (Jacquet, 
Sugarbaker, 1996, Sugarbaker et al., 1996, Kitayama, 2014). As a result, PC 
patients have a bleak prognosis with median survival of only a few months 
(Coccolini et al., 2013) and there is an urgent need for improved therapies. 
 
 
2.1.1. IP chemotherapy for treatment of PC:  
advantages and challenges 
IP chemotherapy was first explored in the 1950s as a palliative tool in patients 
with certain types of peritoneal malignancies to limit the formation of ascites 
(Weisberger, Levine & Storaasli, 1955). In the late 1970s it was hypothesized 
that local administration could be used to increase tumors’ exposure to anti-
cancer drugs to improve treatment efficacy and minimize systemic drug toxicity 
and side effects (Dedrick et al., 1978). Since then, significant efforts have been 
dedicated to pre-clinical and clinical research to study the advantages and 
disadvantages of this challenging route of administration (Lambert, 2015). The 
rationale behind IP administration is based on the recognition that the presence 
of peritoneal-plasma barrier causes the IP drugs to be cleared slowly from the 
peritoneal cavity, resulting in high local drug concentrations- especially for 
higher molecular weight agents (Hasovits, Clarke, 2012). Peritoneal-plasma 
barrier prevents rapid drug resorption from the peritoneal cavity into the circula-
tion and therefore, drug exposure at the tumor site will be increased compared 
to other parts of the body and beyond what would be achieved through systemic 
delivery (Hasovits, Clarke, 2012, Jacquet, Sugarbaker, 1996). This is expressed 
as the area under cavity-to-plasma concentration vs time curve (AUC) (Howell, 
2008). 
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IP drugs have a dual mode of reaching the tumor: in addition to the high 
local concentration of the chemotherapeutic drug and direct access to the tumor, 
IP administered drugs will also enter systemic circulation via small capillary 
blood vessels adjacent to the peritoneum and enter the tumor microcirculation, 
whereas IV administered drugs solely rely on systemic accessibility (Fig.1). 
Therefore, IP delivery route has the advantage of targeting small avascular 
tumor nodules left behind after surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. IP chemotherapy vs. IV chemotherapy. High concentration of chemothera-
peutics can be achieved in the peritoneal cavity with intraperitoneal administration. 
Chemotherapeutic agents enter the tumor through direct surface contact and through 
systemic circulation, after crossing the peritoneal-plasma barrier and entering the blood-
stream (Hasovits, Clarke, 2012). The transport of chemotherapeutics across the endo-
thelium into the capillary lumen occurs via pores and water channels and is regarded to 
be the most critical barrier between the peritoneal surface and circulation (Fujiwara et 
al., 2007). Partially adapted from (Hasovits, Clarke, 2012). 
 
 
Besides physiologically-defined parameters such as IP cavity-to-plasma AUC 
ratio and systemic absorption, the therapeutic efficacy after IP administration, 
the pharmacokinetic profile of drugs is affected by biophysical characteristics 
such as formulation, concentration, and size (Kitayama, 2014, Dakwar et al., 
2017).  
Delivery of chemotherapeutic drugs to PC lesions via the IP route has pharma-
cokinetic and pharmacodynamic advantages over intravenous (IV) administra-
tion. For example, it was reported that compared to the systemic administration 
route, IP-administered mitomycin-C has an improved AUC IP/IV ratio(Jacquet 
et al., 1998a, Van der Speeten et al., 2011). Comparison of IV vs. IP cisplatin in 
patients with stage III ovarian cancer demonstrated significantly improved sur-
vival and fewer toxic effects for the IP administration route (Alberts et al., 1996) 
and a recent systematic review concluded that intraperitoneal chemotherapy 
increases overall survival and progression-free survival from advanced ovarian 
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cancer (Jaaback, Johnson & Lawrie, 2016). However, none of the currently 
available IP chemotherapeutics has passed rigorous testing in clinical trials. At 
present, IP chemotherapy is used off-label with drugs approved for systemic 
anticancer therapy, such as doxorubicin (Jacquet et al., 1998b), paclitaxel (Kuh 
et al., 1999), fluorouracil analogues (Harada et al., 1995), and platinum-based 
drugs (van de Vaart et al., 1998).  
At present, the most widely used therapeutic strategy against peritoneal 
tumors is the hyperthermic intraperitoneal chemotherapy (HIPEC), a procedure 
that includes mild heating of the chemotherapeutic solution (to 41- 42 degrees 
Celsius) to enhance the tumor drug penetration (Flessner, 2016). The applica-
tion of HIPEC to standard treatment regimen aims to decrease the recurrence of 
the disease and HIPEC has become a routine strategy in the treatment of IP 
cancers in many cancer centers (Spiliotis, Halkia & de Bree, 2016, Flessner, 
2016). In combination with cytoreductive surgery, HIPEC improves drug deli-
very to peritoneal tumor lesions and results in modest improvement in short- 
and long-term survival of the PC patients (Armstrong et al., 2006, Elias et al., 
2009, Desiderio et al., 2017, van Driel, Koole & Sonke, 2018). A latest addition 
to IP delivery of cancer drugs is Pressurized IntraPeritoneal Aerosol Chemo-
therapy (PIPAC) – a procedure that involves nebulization of drug solution into 
CO2 pneumoperitoneum during laparoscopy (Grass et al., 2017). 
Unfortunately, IP treatment approaches are far from curing PC, and face 
challenges related to limited therapeutic selectivity, escape of the drug into the 
systemic circulation, and peritoneal toxicities (Yeo, Xu, 2009). The clinical 
efficacy of IP chemotherapeutic drugs depends on its residence time in the 
peritoneal cavity. Drugs with long retention time generally show increased 
tumor accumulation and lower plasma concentration and less side effects (Dak-
war et al., 2017). In contrast, low molecular weight drugs with short IP retention 
time need to be dosed frequently, with increased risk of catheterization-related 
issues (Poveda et al., 2007, Jaaback, Johnson & Lawrie, 2016). Generally, 
molecules <20kDa are rapidly cleared from the IP cavity via the direct absorp-
tion and compounds >20kDa and nanoparticles are eliminated by lymphatic 
drainage. Studies have shown that drug molecules with large molecular weight 
or water insoluble drug molecules (such as taxanes) will be retained in the IP 
cavity longer (Mohamed et al., 2003, Hasovits, Clarke, 2012). In recent years, 
nano- and microformulation of anticancer compounds has been explored as a 
strategy to increase peritoneal retention of drugs for an improved therapeutic 
efficacy and reduction of the number of IP administrations (Dakwar et al., 
2017).  
There is an urgent unmet need to enhance the residence time and/or tumor 
selectivity of the IP chemotherapeutics. The goal is to develop an IP chemo-
therapeutic agent that should specifically accumulate in the tumor tissue and 
should slowly exit the peritoneal cavity; this in turn would maximize tumor 
penetration and optimize cell death while minimizing pan-peritoneal and 
systemic toxicity.  
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2.2. Nanoparticles in detection and  
therapy of malignant disease 
Nanodrugs and -contrast agents are created by encapsulation of bioactive com-
pounds and/or imaging agents into nanoparticles with a size range of 5 to 1000 
nm. Due to unique features of nanoscale carriers, nanomedicine can have a large 
impact of clinical management of malignant disease. Main features are listed 
below: 
(1) Flexibility in payloads. Nanoparticles can be loaded with virtually all 
types of molecular payloads, including hydrophobic agents, compounds that are 
poorly soluble in aqueous solutions, and reactive compounds. Therefore, nano-
particles can be used as formulation aids. For example, AbraxaneTM, a hydro-
phobic microtubule-binding drug paclitaxel packaged in albumin nanoparticles, 
allows to circumvent the injection of hydrophobic paclitaxel in toxic Cremo-
phor solvent (Gradishar et al., 2005). The nanoparticles can accommodate 
combinations of drugs for therapy, imaging agents for improved detection, or 
both for simultaneous treatment and detection of the disease (theranostic nano-
particles) (Shi et al., 2017). 
(2) Engineered effector functions. Nanoparticles can be engineered to exe-
cute effector functions to improve pharmacokinetics and/or pharmacodynamics 
of their payloads. For example, nanoparticles can be programmed to disassemb-
le and release their contents under specific conditions (e.g. at acidic pH found in 
endosomal compartment), or over extended periods for sustained release (Du et 
al., 2011). Affinity ligands can be used to target nanovehicles to normal and 
diseased organs and tissues, and to specific cells or extracellular structures. 
Importantly, low-affinity ligands are well suited for nanoparticle targeting, as 
the targeting ligands are present in multiple copies per particle and copy number 
of targeting ligands can be used to modulate the nanoparticle homing and 
retention at target sites (Ruoslahti, 2017). 
(3) Overcoming the drug resistance. Nanocarrier loading can be used to 
avoid drug resistance due to plasma membrane efflux pumps. Low molecular 
weight drugs typically enter cells by direct penetration of the cell membrane or 
as a result of activity of influx pumps, and can be rapidly exported from cells by 
the activity of multidrug resistance efflux pumps (Goren et al., 2000, Sadava, 
Coleman & Kane, 2002). Drugs loaded on nanoparticles are typically released 
from endosomes deep inside the cell, where the drugs are better positioned to 
exert their activity. 
Several nanoparticles have received regulatory approvals for systemic cancer 
treatment and imaging (Bregoli et al., 2016, Shi et al., 2017), and over 60 clinical 
studies on novel nanoparticle formulations are underway (www.clinicaltrials.gov, 
as on October 24th 2018). The first clinically approved nanodrug, Doxil® (poly-
ethylene glycol-coated liposome-encapsulated doxorubicin), was approved in 
1995, and the second nanodrug, Abraxane® (nanoformulated albumin-bound 
paclitaxel), in 2005. Compared to free compounds, these nanodrugs have 
distinct advantages. Doxil® shows reduced side cardiotoxicity (dose limiting 
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toxicity of doxorubicin) (Gabizon et al., 1994). Abraxane® nanoparticles can be 
administered in aqueous solutions, thus avoiding the use of toxic Cremophor oil 
used as the solvent for free paclitaxel (Gradishar et al., 2005).  
In addition to lipid-based and proteinaceous NPs, polymer-based biocom-
patible and biodegradable nanoparticles, such as poly(lactic-co-glycolic acid) 
(PLGA) (Danhier et al., 2012), have been extensively used in preclinical and 
clinical studies. At present, different nanoparticle platforms are under investiga-
tion for the treatment of cancer including: lipid-based, polymer-based, inorganic 
nanoparticles, viral and drug-conjugated nanoparticles (Figure 2). In each case, 
the choice of NP platform depends on the physicochemical characteristics and 
pharmacokinetic and -dynamic profile of the payload drugs (Wicki et al., 2015, 
Shi et al., 2017).  
 
                         
 
Figure 2. Schematic representation of clinical-stage nanomedicines for cancer therapy. 
A variety of nanocarriers such as lipid-based, polymer-based, inorganic nanoparticles 
currently used in clinical research for cancer. Partially adapted from Wicki et al., 2015. 
 
2.2.1. Polymeric nanoparticles 
Polymeric nanoparticles, or polymersomes (PS), are nanoscale vesicles formed 
by self-assembly of amphiphilic block copolymers in aqueous media (Gaitzsch, 
Huang & Voit, 2016). PS, assembled from low glass transition temperature 
“rubbery” polymers, are flexible and able to pass through pores up to an order 
of magnitude smaller than their diameter (Battaglia, Ryan, 2005, Gaitzsch, 
Huang & Voit, 2016, Pegoraro et al., 2014). Polymersomes are compatible with 
many types of cargoes, and and can be loaded with hydrophobic water insoluble 
drugs (e.g. Paclitaxel) in the membrane and hydrophilic drug molecules in the 
aqueous core. The incorporation of drugs inside the polymersome lumen can 
improve the therapeutic index by circumventing the use of toxic solvents. 
Poly(oligoethylene glycol methacrylate)-poly(2-(diisopropylamino)ethyl metha-
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crylate) (P[(OEG)10MA]20-PDPA90; POEGMA-PDPA) PS are pH sensitive: 
they are stable at physiological pH and disassemble under mildly acidic pH due 
to the protonation of the PDPA block (Bermudez et al., 2002, Pegoraro et al., 
2014). This property of POEGMA-PDPA vesicles renders them particularly 
well suited for intracellular cargo delivery: after cellular internalization, the PS 
disassemble at endosomal acidic pH followed by endosomal rupture due to 
proton sponge effect and release of cargo in the cytosol (Massignani et al., 
2009, Simon-Gracia et al., 2016b). PS have been used for intracellular delivery 
of DNA (Lomas et al., 2007), antibodies (Canton et al., 2013, Wang et al., 2012, 
Tian et al., 2015), antibiotic compounds (Wayakanon et al., 2013) cytotoxic 
drugs (Pegoraro et al., 2013, Colley et al., 2014, Simon-Gracia et al., 2016b), 
and bioactive peptides (Chierico et al., 2014).  
 
 
2.2.2. Iron oxide nanoworms  
Timely and precise detection of malignant disease and application of effective 
and well-tolerated therapeutic regimen are critically important for successful 
cancer treatment. Classic cancer detection techniques rely on imaging of anato-
mical features, whereas molecular imaging uses specific molecular probes to 
image biochemical activities, or specific receptors overexpressed in the tumor 
environment (Elias et al., 2008). Molecular imaging allows early detection of 
cancer and, at later stages, monitoring of changes in molecular behavior and 
host responses related to stage-specific events in disease progression in mole-
cular and cellular levels (Weissleder, 2006).  
Magnetic Resonance Imaging (MRI)-active iron oxide (IO) NPs can be 
engineered to have different chemical composition, size, and shape (Sun, Lee & 
Zhang, 2008). The biological behavior of the particles is profoundly affected by 
particle coating with molecules designed to decrease their nonselective uptake 
(e.g. PEG and dextrans) and with affinity ligands to allow precision delivery to 
intended target cells and -tissues (Kudr et al., 2017). The flexibility and low 
toxicity of IONPs have led to their applications in preclinical cancer research 
(Fang, Zhang, 2009). First generation of IONPs was designed for diagnostic 
applications and to accumulate in tumors (1) passively due to the enhanced 
permeability and retention (EPR) effect (discussed below), or (2) with the help 
of affinity ligands attached to the NP surface. The second generation of IONPs 
combines both therapeutic and/or diagnostic functions. For example, IONPs 
loaded with doxorubicin showed promising results against liver cancer in rats 
and rabbits (Maeng et al., 2010), peptide-guided IONPs and folic acid receptor-
targeted IONPs improved MRI contrast and appeared to be promising agents for 
the detection of human ovarian and breast cancer, respectively (Abulrob et al., 
2018, Zhang et al., 2016). IONPs can be engineered to exert anticancer effector 
functions: delivery of drugs, genes, and photothermal agents, or induction of 
magnetic hyperthermia (Li, Nejadnik & Daldrup-Link, 2017). For example, intra-
tumorally-injected IONPs (Nanotherm®) can be heated up by an alternating 
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magnetic field – a procedure approved by EMA in 2012 for the treatment of 
glioblastoma in combination with radiotherapy and/or chemotherapy (Alphan-
dery et al., 2015). Despite all the pre-clinical research on smart IONPs, only 
non-functionalized IONP formulations have been clinically approved for diag-
nostics (e.g. Feraheme®, Feridex®; Resovist®; Combidex®) (Zhu et al., 2017). 
IONPs can be imaged by MRI also in other diseases such as inflammatory and 
degenerative pathologies, and in demyelinating disease, multiple sclerosis (Vel-
linga et al., 2009, Stoll, Bendszus, 2009, Gobbo et al., 2015).  
Iron oxide nanoworms (NWs) – elongated PEGylated dextran-coated para-
magnetic IONPs – are a subclass of IONPs optimized for in vivo precision-
guided delivery. Compared to spherical IONPs, the elongated form of NWs is 
better suited for targeted delivery applications due to geometrically-enhanced 
multivalent interactions between receptors and ligands (Park et al., 2009). NWs 
show low toxicity, long plasma half-life, and a robust ability to enhance MRI 
relaxivity (Park et al., 2009, Ruoslahti, 2017). Systemically administered thera-
peutic nanoworms carrying D [KLAKLAK]2 proapoptotic peptide payload and 
functionalized with tumor homing peptides accumulate in mouse models of 
breast tumors and glioblastoma and dramatically improve antitumor activity and 
therapeutic index of proapoptotic cargo (Agemy et al., 2013, Agemy et al., 
2011, Sharma et al., 2017).  
 
 
2.3. Tumor-selective delivery of drugs and nanoparticles 
Targeted drug delivery in cancer utilizes drug delivery systems (nanocarriers) to 
change the pharmacological properties of conventional drugs to modulate their 
biodistribution towards increased accumulation in tumor tissue for improved 
tumor imaging (diagnostic NPs), therapeutic outcome (therapeutic NPs), or both 
(theranostic NPs). The aim is to achieve tumor-selective drug delivery to im-
prove therapeutic index of drugs – the difference in the concentration of thera-
peutic agent that causes the therapeutic effect and the toxic concentration.  
Currently no clinically approved nanoparticle drugs have targeting ligands 
attached to their surface (Shi et al., 2017). Non-targeted NPs are thought to 
accumulate in the tumor tissue passively, due to an effect known as Enhanced 
Permeability and Retention (EPR). The EPR concept, introduced by Hiroshi 
Maeda in 1986, states that blood vessels in tumor tissue have compromised 
vascular wall and are hyperpermeable, and that this leakiness translates into 
tumor-selective delivery of circulating payloads, including nanoparticles 
(Matsumura, Maeda, 1986). The absence of functional lymphatics vessels in 
most tumors further contributes to the nanoparticle entrapment and retention at 
the tumor site (Fang, Nakamura & Maeda, 2011). However, the EPR effect is 
not universal, and shows large degree of intra- and intertumoral heterogeneity 
(Danhier, 2016).  
In contrast to passive targeting, affinity-based targeting (also termed synaphic, 
pathotrophic, or active targeting) uses targeting ligands that interact with 
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accessible molecular markers in the tumor environment for direct drug delivery. 
The intended outcome of this approach, zeroing-in on the target tissue, is 
comparable to topical administration with high local and low systemic exposure 
(Ruoslahti, Bhatia & Sailor, 2010). Over the years, the most common affinity 
targeting approach to deliver anti-cancer drugs and imaging agents to solid 
tumors is using antibodies and their fragments. Various monoclonal antibodies 
have reached the clinical use such as Trastuzumab (for breast cancer), Bevaci-
zumab (for colorectal cancer), Cetuximab (for colorectal cancer) and many 
more (Trail, King & Dubowchik, 2003, Adams, Weiner, 2005). One of the 
fastest growing drug classes in oncology are Antibody-Drug Conjugates 
(ADCs). ADCs combine the selectivity and high affinity of antibodies with 
potency of chemotherapeutic molecules (Perez et al., 2014). The aim thriving 
ADC research has been to improve the therapeutic index of chemotherapeutics 
by lowering the minimum effective dose and increasing the maximum tolerated 
dose (Beck et al., 2010). Currently the only ADCs approved by the FDA and 
EMA are Kadcyla®, an anti-human epidermal growth factor receptor-2 (HER2) 
with a maytansinoid payload for breast cancer therapy, and Adcetris® 
(brentuximab vedotin) with MMAE (monomethyl auristatin E) targeting 
CD30-positive Hodgkin’s Lymphoma (Senter, Sievers, 2012, Lambert, Chari, 
2014). These two approved ADCs have paved the way for ongoing clinical 
trials with more than 60 investigational ADC candidates (Beck et al., 2017). 
In addition to ADCs, four nanoparticles with chemotherapeutic payloads 
and coated with affinity ligands recognizing for example HER2, PSMA (pro-
state specific membrane antigen), EGFR and TfR (transferrin receptor) are 
currently being evaluated in clinical trials for different types of solid tumors, 
including gastric adenocarcinoma (Shi et al., 2017). Nevertheless, antibodies 
have disadvantages that limit their clinical application, including high manu-
facturing cost, low ability to extravasate and reach parenchymal target cells due 
to large size and high affinity (that causes affinity site barrier) and immuno-
genicity (Liu, Wu, 2008). In contrast, peptides as affinity ligands are affordable 
and have shown good tissue penetrating ability due to their small size, low 
immunogenicity, multivalent presentation on a NP and can be readily coupled 
to different classes of molecular payloads using well-established chemistries 
(Ruoslahti, Bhatia & Sailor, 2010, Ruoslahti, 2012).  
 
 
 2.4. Nanoparticles in PC 
Formulation has a profound effect on the pharmacokinetics, biodistribution, and 
efficacy of the drugs. Nano- and microformulation of anticancer compounds can 
increase peritoneal retention of drugs that translates into an improved thera-
peutic efficacy and reduction of the number of IP administrations (Dakwar et 
al., 2017). As nanoparticles enter cells via endocytosis, loading of drugs in 
nanoparticles can also bypass or alleviate drug resistance due to overexpression 
of drug efflux pumps. In the context of IP-targeted nanotherapies, the main 
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areas of investigation are extension of the drug residence time in the IP cavity, 
increasing the specificity towards cancer cells, and limiting the side effects.  
 
 
2.4.1. Nanoparticles in pre-clinical development  
for PC therapy 
Different types of nontargeted nanoparticles have been evaluated for intra-
peritoneal delivery in the PC (of colorectal, gastric, ovarian carcinoma origin) 
bearing mice. These include lipid-based NP formulations and polymer-based 
NPs (such as polymersomes, polymeric microspheres and hydrogel-based 
systems). The NP-encapsulated drug payloads include paclitaxel, doxorubicin, 
5-fluorouracil (5-FU), and docetaxel (Van Oudheusden et al., 2015). For 
example, Emoto et al. used in their study micellar nanoparticle platform loaded 
with Paclitaxel for treatment of MKN-45P gastric cancer xenografts, and 
observed enhanced NP penetration into tumor nodules and significant decrease 
in tumor nodules and tumor weight compared to free Paclitaxel-Cremphor-
treatment (Emoto et al., 2012). In another study, Fan and colleagues found that 
IP-administered polymer-based thermosensitive hydrogel based on polylactic 
acid and Pluronic L64 loaded with combination of chemotherapeutic drug 
docetaxel and anti-tumor peptide LL37, reduced significantly the growth of 
colorectal cancer peritoneal xenografts in nude mice (Fan et al., 2015). In 
addition, this system increased the survival of the treated mice compared to the 
control groups. Additional polymer-based delivery systems for PC have been 
evaluated for IP targeting of PC (Liu et al., 2013a, Gong et al., 2012, Soma et 
al., 2009, Vassileva et al., 2007). 
Several studies have addressed the effect of affinity targeting on the tumor 
distribution and efficacy of IP-administered drug-loaded NPs. Folic acid 
receptor -α (FR-α) upregulation is commonly seen in ovarian cancer lesions 
(Elnakat, Ratnam, 2006). Cerium oxide NPs have antitumor activity due to 
increase in production of reactive oxygen species (ROS) (Hijaz et al., 2016). 
Coating of the cerium oxide NPs with folic acid increased their cellular 
internalization and decreased cell proliferation in cultured ovarian cancer cells. 
In addition, when the folic acid guided-NPs were IP-administered in ovarian 
PC-bearing mice in combination with a known chemotherapeutic drug cisplatin, 
the tumor burden in mice was decreased (Hijaz et al., 2016). Similar results 
were reported when folic acid–guided nano-paclitaxel liposomes were ad-
minstered to ovarian cancer xenograft model in mice via IP injection (Tong et 
al., 2014). 
In another study, coupling of tumor homing peptide F3 to α-particle-emitting 
radionuclides was found to improve survival of PC-bearing mice compared to 
the untreated control mice and control group treated with non-targeted radio-
nuclides (Essler et al., 2012). In another study, application of integrin-targeting 
tripeptide RGD coupled to fluorescent dye indocyanine green (RGD-ICG) 
allowed image guided surgery with shorter time for surgery and more complete 
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removal of malignant tissue (Cheng et al., 2017). Remarkably, the diameter of 
detectable tumor nodules was <2 mm and compared to conventional surgery the 
time required for surgery using RGD-ICG was decreased ~3 fold (Cheng et al., 
2017). 
 
 
2.4.2. Therapeutic nanoparticles in PC clinical trials 
Two untargeted NP formulations are currently being assessed for IP tumor 
therapy in clinical trials (Table 1). The first study, a phase I trial, assessed the 
safety, tolerability and pharmacokinetic profile of IP administered Cremophor-
free Paclitaxel (Nanotax®) in patients bearing solid tumors confined to the 
peritoneal cavity (Williamson et al., 2015). The patients received six escalating 
IP doses of Nanotax® over 28 days. The study concluded that compared to IV 
administration IP administration results in reduced systemic toxicity and im-
proved PK profile. Nanotax®, a ~700 nm rod-shaped nanoformulation of 
paclitaxel is retained in the peritoneal cavity and shows minimal escape to the 
systemic circulation. Two days after the injection of Nanotax® the concentration 
of paclitaxel in peritoneal fluid was 450–2900 fold higher than in plasma. The 
study was completed in 2013 and it is not clear wether a Phase II trial will be 
initiated.  
The second Phase I study evaluated the maximally tolerated dose, adverse 
effects and the pharmacokinetics of IP administered Abraxane®, an albumin-
bound paclitaxel nanoformulation that was approved in 2005 for the treatment 
of metastatic breast cancer (Cristea et al., 2015). The study on 27 patients con-
cluded that IP administered Abraxane has pharmacologic advantage over IV 
administered Abraxane and the inter- and intra-patient variability in drug uptake 
is low. The study completion date was 16th of January 2018. Presumably the final 
results will be published in the near future (Clinical Trial no. NCT00825201). 
There have been no clinical trials on affinity targeted NPs for PC.  
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2.5. Tumor homing peptides 
Vascular heterogeneity can be explored in unbiased manner by in vivo screening 
of phage libraries that display random peptide sequences (Hoffman et al., 2003, 
Pasqualini, Ruoslahti, 1996). The process of tumor homing peptide biopanning 
consists of intravenous administration of phage library into a tumor-bearing 
mouse, rescuing the phage from the malignant tissue, and repeating the process 
several times to derive a phage pool that selectively homes to the tumor. When 
peptide phage libraries are injected into the circulation, tumor-specific mole-
cules on endothelial cells are primarily targeted. Phage display has yielded 
numerous peptides specific for many different conditions as summarized in 
Table 2. Importantly, this approach has yielded a variety of homing peptides 
specific for tumor vasculature and tumor cells (Arap, Pasqualini & Ruoslahti, 
1998, Laakkonen et al., 2002, Ruoslahti, 2004, Fan et al., 2007, Zhang et al., 
2006).Tumor homing peptides can be used for precision guided delivery of 
coupled drugs and contrast agents to tumor blood vessels to improve tumor 
detection and increase therapeutic index (Liu et al., 2017a). Coupled to tumor-
homing peptides, different anti-cancer drugs show an enhanced anti-tumor 
effect (Arap, Pasqualini & Ruoslahti, 1998, Ellerby et al., 1999, Chen et al., 
2001, Curnis et al., 2000, Karmali et al., 2009).  
25
 
Ta
ble
 2.
 Ex
am
ple
s o
f h
om
ing
 pe
pti
de
s a
nd
 th
eir
 in
 v
iv
o h
om
ing
 sp
eci
fic
ity
. A
do
pte
d f
rom
 Te
esa
lu 
et 
al.
, 2
01
2. 
Pe
pti
de
 Se
qu
en
ce 
In
 v
iv
o h
om
ing
 sp
eci
fic
ity
 
Re
fer
en
ce 
1. 
AK
RG
AR
ST
A 
 (li
nT
T1
) 
2. 
CK
RG
AR
ST
C 
(T
T1
) 
Pe
rito
ne
al 
tum
ors
 (p
32
/N
RP
-1)
 
Br
eas
t tu
mo
rs 
(p3
2/N
RP
-1)
 
Br
eas
t tu
mo
rs 
(p3
2/N
RP
-1)
 
(H
un
t e
t a
l., 
20
17
, S
ha
rm
a e
t a
l., 
20
17
, 
Pa
aso
ne
n e
t a
l., 
20
16
)  
 
3. 
CS
PG
AK
VR
C 
 (U
NO
) 
Tu
mo
r m
acr
op
ha
ge
s (
CD
20
6) 
(S
co
de
lle
r e
t a
l., 
20
17
) 
4. 
RP
AR
SG
RS
AG
GS
VA
 
  (u
Ce
nd
R)
 
Br
eas
t tu
mo
rs 
(N
RP
-1)
 
(B
rau
n e
t a
l., 
20
16
) 
5. 
CA
QK
 
Br
ain
 in
jur
y 
(M
an
n e
t a
l., 
20
16
) 
6. 
CK
RD
LS
RR
C 
  (I
P3
) 
Pe
rito
ne
al 
tum
ors
 
(Ik
em
oto
 et
 al
., 2
01
7) 
7. 
CD
AG
RK
QK
C 
 (D
AG
) 
Al
zh
eim
er´
s d
ise
ase
 
(M
an
n e
t a
l., 
20
17
) 
8. 
CR
NG
RG
PD
C 
(iN
GR
) 
Br
eas
t tu
mo
rs 
(C
D1
3/N
RP
-1)
 
(A
lbe
ric
i e
t a
l., 
20
13
) 
9. 
CG
KR
K 
Br
eas
t tu
mo
rs 
(p3
2) 
Gl
iob
las
tom
a (
p3
2) 
Sq
ua
mo
us
 ce
ll c
arc
ino
ma
 (p
32
) 
(A
ge
my
 et
 al
., 2
01
3, 
Ag
em
y e
t a
l., 
20
11
, 
Ho
ffm
an
 et
 al
., 2
00
3) 
10
. R
PA
RP
AR
 
Pr
oto
typ
ic 
Ce
nd
R 
pe
pti
de
 (N
RP
-1)
 
(T
ees
alu
 et
 al
., 2
00
9) 
11
. C
RG
DK
GP
DC
  (i
RG
D)
 
Di
ffe
ren
t tu
mo
rs;
 pr
oto
typ
ic 
tis
su
e p
en
etr
ati
ng
 pe
pti
de
 (α
vβ
3/5
 
int
erg
rin
s; 
NR
P-1
) 
(Su
ga
ha
ra 
et 
al.
, 2
00
9) 
12
. C
AG
AL
CY
 
Br
ain
 
(F
an
 et
 al
., 2
00
7) 
13
. C
RE
KA
 
An
gio
ge
nic
 ve
sse
ls 
(fi
bri
n c
lot
s) 
(Si
mb
erg
 et
 al
., 2
00
7) 
14
. C
AR
SK
NK
DC
  (C
AR
) 
15
. C
RK
DK
C 
 (C
RK
) 
W
ou
nd
 
W
ou
nd
 
(Ja
rvi
ne
n, 
Ru
osl
ah
ti, 
20
07
) 
16
. C
RA
KS
KV
AC
 
Pa
n-e
nd
oth
eli
al 
ho
me
r 
(Z
ha
ng
 et
 al
., 2
00
6) 
17
. C
RE
AG
RK
AC
 
18
. C
AG
RR
SA
YC
 
Pro
sta
te 
car
cin
om
a l
ym
ph
ati
cs 
Pro
sta
te 
car
cin
om
a p
rem
ali
gn
an
t ly
mp
ha
tic
s 
(Z
ha
ng
 et
 al
., 2
00
6) 
19
. C
LS
DG
KR
KC
 
Ly
mp
ha
tic
s i
n C
81
61
 m
ela
no
ma
 
(Z
ha
ng
 et
 al
., 2
00
6) 
20
. C
NR
RT
KA
GC
  (L
yP
-2)
 
K1
4H
PV
16
 dy
spl
ast
ic 
sk
in 
les
ion
s 
(Z
ha
ng
 et
 al
., 2
00
6) 
21
. C
GL
IIQ
KN
EC
  (C
LT
1) 
22
. C
NA
GE
SS
KN
C 
(C
LT
2) 
Bl
oo
d c
lot
 
Bl
oo
d c
lot
 
(P
ilc
h e
t a
l., 
20
06
) 
26
 
Pe
pti
de
 Se
qu
en
ce 
In
 v
iv
o h
om
ing
 sp
eci
fic
ity
 
Re
fer
en
ce 
23
. C
RP
PR
 
He
art
 
 
(Z
ha
ng
, H
off
ma
n &
 R
uo
sla
hti
, 2
00
5) 
24
. C
GN
KR
TR
GC
  (L
yP
-1)
 
Tu
mo
r ly
mp
ha
tic
s, 
tum
or 
ma
cro
ph
ag
es 
an
d t
um
or 
ce
lls
 in
 
hy
po
xic
 ar
ea
s (
p3
2/ 
NR
P-1
) 
(L
aak
ko
ne
n e
t a
l., 
20
02
) 
25
. C
SR
PR
RS
EC
 
Dy
sp
las
tic
 sk
in 
(H
off
ma
n e
t a
l., 
20
03
) 
26
. g
SM
SI
AR
L 
27
. g
VS
FL
EY
R 
No
rm
al 
pro
sta
te 
No
rm
al 
pro
sta
te 
(A
rap
 et
 al
., 2
00
2) 
28
. C
TT
HW
GF
TL
C 
Ge
lat
ina
se 
A 
in 
an
gio
ge
nic
 ve
sse
ls 
(K
oiv
un
en
 et
 al
., 1
99
9) 
29
. C
NG
RC
 
An
gio
ge
nic
 ve
sse
ls 
(C
D1
3) 
(A
rap
, P
asq
ua
lin
i &
 R
uo
sla
hti
, 1
99
8) 
30
. C
RR
ET
AW
AC
  
α5
β1
 in
teg
rin
s 
(K
oiv
un
en
, W
an
g &
 R
uo
sla
hti
, 1
99
4) 
   
27 
2.5.1. Tumor penetrating peptides and the C-end Rule  
The power of in vivo phage screening is illustrated by the recent discovery of 
peptides with unique tumor-penetrating properties. These tumor penetrating 
peptides (TPP) activate an endocytic transport pathway related to, but distinct 
from macropinocytosis by engaging a complex process that involves binding to 
a primary, tumor-specific receptor, a proteolytic cleavage, and binding to a 
second receptor, neuropilin-1 (NRP-1). The NRP-1 binding activates the 
transport pathway (Pang et al., 2014, Teesalu et al., 2009). NRP-1 has a binding 
pocket on its b1 domain that is capable of interacting with C-terminal peptides 
with consensus sequence R/KXXR/K (x-random amino acid). Such R/KXXR/K-
containing peptides are due to strict requirement for C-terminal exposure 
termed C-end rule (Teesalu et al., 2009, Sugahara et al., 2009). The CendR 
receptor, NRP-1, is a pleiotrophic cell surface receptor with essential roles in 
angiogenesis, regulation of vascular permeability and development of the 
nervous system (Geretti, Klagsbrun, 2007, Gagnon et al., 2000). VEGF-A165 
and some other ligands of NRP-1 possess a C-terminal CendR sequence that 
interacts with the b1 domain of NRP-1 and causes cellular internalization and 
vascular leakage (Becker et al., 2005). CendR peptides have similar effects, 
particularly when made multivalent through coupling to a molecular scaffold or 
a particle (Teesalu et al., 2009). NRP-1 is widely expressed in normal tissues 
and overexpressed in variety of tumors and tumor cell lines, including gliomas 
(Hu et al., 2007). Interestingly, overexpression of NRP-1 is correlated with poor 
prognosis of human glioma (Osada et al., 2004), and peptide-based interference 
of the transmembrane domain of NRP-1 appears to inhibit growth of orthotopic 
C6 glioma model by exerting anti-migratory, anti-angiogenic and anti-pro-
liferation activity (Nasarre et al., 2010).  
The trans-tissue CendR pathway mediates the exit of payloads from the 
blood vessels and their transport through extravascular tumor tissue. The CendR 
technology provides a solution to a major problem in tumor therapy, poor pene-
tration of drugs into tumors. The tumor-penetrating CendR peptides can take a 
payload deep into tumor tissue in mice and into human tumors ex vivo. Tumor-
penetration is seen even when the tumor is highly desmoplastic, as typically 
seen in the case of pancreatic tumors (Sugahara et al., 2009). These peptides 
specifically increase the accumulation in tumors of a variety of anticancer 
therapeutics, such as chemotherapeutic agents, antibodies and, particularly 
relevant to this application, therapeutic nanoparticles (NPs). Remarkably, the 
payload to be targeted does not have to be coupled to the peptide; the peptide 
activates a bulk transport system that sweeps along any compound present in 
the blood (“by-stander effect”). Treatment studies in mice show improved anti-
tumor efficacy and less damage to normal tissues (Sugahara et al., 2009, 
Sugahara et al., 2010, Agemy et al., 2011, Alberici et al., 2013, Gu et al., 2013, 
Akashi et al., 2014, Wang et al., 2014, Schmithals et al., 2015, Zhang et al., 
2015, Liu et al., 2013b, Liu et al., 2017b). In addition to a systemic route, the 
tumor penetrating peptides access tumors and induce the bystander effect by 
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direct contact with tumor tissue, including ex vivo tumor tissue “dipping” assay 
(Sugahara et al., 2009, Sugahara et al., 2010). The nature and regulation of the 
CendR pathway is partially understood; it is an endocytic transcytosis pathway 
that is regulated by availability of nutrients to a tumor and triggered through 
peptide binding to NRP-1 (Pang et al., 2014). 
 
 
2.5.1.1. iRGD 
The prototypic TPP iRGD (CRGDK/RGPD/EC) homes to angiogenic αv and 
β3/5 integrins expressed on plasma membrane of endothelial, fibroblast and 
malignant cells in tumors (Ruoslahti, 2012). After recruitment to integrins 
iRGD is proteolytically cleaved to expose C-terminally CRGDK CendR motif, 
and the truncated peptide loses most of its integrin-binding capacity and gains 
affinity for neuropilin-1 (NRP-1) (Figure 2). The proteolytic activation of the 
CendR sequence requires the integrin binding; the CendR motif is only mini-
mally activated in an analogue (CRGEKGPDC) that lacks affinity for integrins 
(Sugahara et al., 2009). The likely reason is that the proteolytic processing step 
can only occur in close proximity to the cell surface. The αv integrin require-
ment makes iRGD activation specific to angiogenic tumor vessels. The tumor-
penetrating properties of iRGD are in striking contrast to those of other RGD 
peptides that bind to αv integrins with affinities like that of iRGD but lack a 
CendR motif. Figure 3 depicts a multistep binding and penetration mechanism 
of iRGD peptide. 
 
 
Figure 3. TPP multistep binding and penetration mechanism. iRGD peptide is recruited 
to integrins expressed on endothelial cells and other cells in tumors. After recruitment to 
integrins, iRGD is proteolytically cleaved to expose C-terminally CRGDK CendR 
motif, and the truncated peptide loses most of its integrin-binding capacity and gains 
affinity for neuropilin-1 (NRP-1). Binding to NRP-1 mediates penetration to cells and 
tissues. Adopted from Sugahara et al., 2009. 
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iRGD can be used to increase vascular and tissue permeability in a tumor-
specific and neuropilin-1-dependent manner to enhance the penetration of 
chemically conjugated and co-administered anticancer drugs, imaging agents, 
and nanoparticles (Sugahara et al., 2009, Sugahara et al., 2010). iRGD is 
clinically developed for co-administration-based delivery of drugs and imaging 
agents to pancreatic cancer by a biotechnology company in the US, DrugCendR 
Inc. (www.drugcendr.com).  
 
 
2.5.1.2. TT1 
Another recently identified TPP, TT1 (cyclic TT1: CKRGARSTC; linear TT1: 
AKRGARSTA), is highly efficient in delivery of molecular and nanoparticle 
payloads to breast cancer lesions (Paasonen et al., 2016, Sharma et al., 2017, 
Simon-Gracia et al., 2018). The primary homing receptor for TT1 is p32, a 
mitochondrial protein aberrantly expressed on the cell surface of activated 
malignant and stromal cells in solid tumors (Fogal et al., 2008). TT1 peptide is 
after binding to p32 proteolytically cleaved to expose C-terminally the RGAR 
peptide that interacts with tissue penetration receptor NRP-1 (Sugahara et al., 
2009, Teesalu et al., 2009, Sharma et al., 2017).  
 Cell surface p32 became relevant for systemic affinity targeting as the 
receptor for LyP-1 peptide that targets lymphatic vessels and macrophages 
(Laakkonen et al., 2002, Fogal et al., 2008). LyP-1 is widely used as an affinity 
module for tumor delivery of imaging agents, drugs, and nanoparticles to solid 
tumors (Luo et al., 2010, Yan et al., 2012, Roth et al., 2012, Miao et al., 2014, 
Timur et al., 2017, Teo et al., 2018). Success of LyP-1-based affinity targeting 
has inspired development of alternative targeting ligands to p32, including other 
homing peptides, antibodies, and low molecular weight compounds (Agemy et 
al., 2011, Paasonen et al., 2016, Kim et al., 2016, Yenugonda et al., 2017). P32 
is prominently expressed in clinical samples and in mouse models of glioblasto-
ma, and there is a significant correlation between high p32 expression and 
decreased survival of glioblastoma patients (Fogal et al., 2015). LyP-1 and 
several p32 targeting ligands possess an intrinsic antitumor activity (Laakkonen 
et al., 2004); in addition, genetic knockdown of p32 has been demonstrated to 
limit cell proliferation in vitro and tumor growth in vivo (Fogal et al., 2015). It 
is likely that alignment of intrinsic anticancer activity of LinTT1 with nano-
particle payload drugs that act in synergy can be used to potentiate the thera-
peutic efficacy of p32-directed nanosystems.  
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SUMMARY OF THE LITERATURE 
Gastrointestinal and gynecological malignancies often disseminate in the perito-
neal cavity. The condition is known as peritoneal carcinomatosis (PC) and it 
may cause complications such as bowel obstruction and the formation of 
ascites. PC results from the dissemination of the primary tumor or seeding after 
surgical intervention and is a cause for incurability of intra-abdominal cancers. 
In the treatment of peritoneal tumor lesions, intraperitoneal chemotherapy can 
be used to improve delivery of drugs into peritoneal tumors by providing direct 
contact and higher local concentration. Intraperitoneal chemotherapy was first 
introduced as a palliative tool to alleviate the symptoms arising from the forma-
tion of ascites in certain cancers. Later the approach was used in combination 
with cytoreductive surgery to kill the remaining micrometastasis that were 
impossible to remove during surgery.  
IP chemotherapy is an attractive strategy to improve the outcome of PC. Du-
ring the last decades, substantial amount of work has been put into improving 
the therapeutic outcome of PC by applying different therapeutic approaches that 
maximize selectivity and limit side effects. Multiple studies suggest that a deli-
very of chemotherapeutic drugs via IP route is a promising method and offers a 
direct pharmacokinetic advantage over intravenous (IV) administration. IP 
administration of drugs results in higher local concentrations and longer half-
life of the drug in the peritoneal cavity thus improved outcome of the chemo-
therapy is achieved. Nanoparticles in the context of direct targeting of IP tumors 
are actively being evaluated in preclinical studies due to their potential of 
increasing the retention time in the IP cavity and to target drugs specifically to 
the tumor site compared to the conventional drugs. A few nanoparticle formula-
tions of chemotherapeutic drugs have reached human trials, but there are no 
approved drug formulations for the specific use in the IP cavity. 
Novel strategies such as development of precision nanomedicines to speci-
fically target cancerous lesions and development of drugs/nanoparticles with 
extended residence time in the IP cavity may help to increase efficacy of IP 
chemotherapy. 
 
  
31 
3. AIMS OF THE STUDY 
The goal of the research presented in this dissertation was the development of 
TPP-NP platform for IP delivery of anticancer drugs and imaging agents. A 
panel of complementary strategies were used to study the homing and anti-
cancer efficacy of the peptide-guided therapeutic NPs on cultured malignant 
cells and in vivo, after IP administration into tumor bearing mice. 
 
Specific aims: 
1. To establish the specificity profiles for TPP-NP under cell-free conditions 
and on cultured IP tumor cell lines; 
2. To determine the effect of TPP functionalization on the cellular uptake and 
cytotoxic activity of the NPs loaded with imaging agents and cytotoxic 
payloads; 
3. To determine the effect of TPP functionalization on the IP tumor tropism 
and biodistribution of the IP administered NPs; 
4. To evaluate the therapeutic efficacy of IP treatment of experimental PC 
using TPP-guided cytotoxic NPs. 
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4. MATERIALS AND METHODS 
The methods used in the research presented in this thesis are described in detail 
in the respective publications. This section provides brief summary of the 
methods used in the studies. 
 
 
4.1. Cell culture experiments and animal studies 
We used five different cancer cell lines that originate from human or mouse 
tissues (Table 3). MKN-45P cells were isolated from parental MKN-45 cells 
(Koga et al., 2011). SKOV-3 and CT-26 cell lines were purchased from ATCC 
(SKOV-3 ATCC HBT-7; CT-26 ATCC CLR-2638). PPC-1 cancer cells were 
from the Ruoslahti laboratory at Sanford-Burnham-Prebys Medical Discovery 
Institute (SBPMDI), and M21 cells were a gift from David Cheresh at Uni-
versity of California San Diego (UCSD). The cells were cultivated in DMEM 
(Lonza, Belgium) containing 100 IU/mL of penicillin, streptomycin, and 10% 
of heat-inactivated fetal bovine serum (GE Healthcare, UK) in 5% CO2 atmo-
sphere.  
For animal experimentation athymic nude mice were purchased from Harlan 
and Balb/c mice were purchased from Charles River. Animal experimentation 
protocols were approved by Estonian Ministry of Agriculture, Committee of 
Animal Experimentation (Project #42).  
 
 
Table 3. Cell-lines used in the in vitro and in vivo studies 
Cell-line name Surface receptor Application Publication 
in thesis NRP-1   p32 
MKN-45P Human gastric carcinoma 
+ + In vitro /In vivo 
Nude mice 
I–IV 
CT-26 Mouse colon carcinoma 
+ + In vitro /In vivo 
Balb/c mice 
I–IV 
SKOV-3 Human ovarian carcinoma 
+ + In vitro /In vivo 
Nude mice 
I; III 
PPC-1 Human prostate adenocarcinoma 
+ + In vitro II 
M21 Human melanoma - + In vitro II 
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4.2. Peptides and targeted nanoparticles 
Peptides used in this thesis (Table 4) were synthesized using Fmoc/t-Bu che-
mistry on a microwave assisted automated peptide synthesizer (Liberty, CEM 
Corporation, NC, USA). Peptides were purified by HPLC using 0.1% TFA in 
acetonitrile-water mixtures to 90% – 95% purity and validated by Q-TOF mass 
spectral analysis. Fluorescent peptides were synthesized by using 5(6)-carbo-
xyfluorescein (FAM) with 6-aminohexanoic acid spacer attached to the N-
terminus of the peptide. 
Three different nanoparticle (NP) platforms are used in this thesis (Fig. 4). 
All have recently been reported to facilitate nanoscale delivery of payloads to 
tumors (Sharma et al., 2017, Simon-Gracia et al., 2016a, Toome et al., 2017), 
but not been evaluated as delivery vehicles for IP tumor targeting. In publica-
tion I, we utilized for IP cancer targeting and imaging dextran-coated iron oxide 
nanoworms (NW) – theranostic NPs that serve as a carrier for anticancer 
compounds and possess intrinsic T2 contrast in MRI. In publications II and III 
we evaluated nontargeted and targeted pH-sensitive PS (PS), nanocarriers that 
can be loaded with hydrophobic chemotherapeutics, for treatment for IP tumors. 
In publication IV we used AgNP platform to show the homing of hyaluronic 
acid (HA) binding peptide to the IP tumors.  
 
 
Table 4. TPP and NP platforms used in this thesis. 
Peptide Amino acid 
sequence 
Receptor 
(homing 
specificity) 
Nanoparticle 
platform 
Publication 
in thesis 
LinTT1 
(KLAKLAK)* 
AKRGARSTA 
D(KLAKLAK)2 
p32 NW I 
iRGD CRGDKGPDC αv integrins; 
NRP-1 
PS; NW I–II 
RPAR / R GRPARPAR NRP-1 PS; NW I–II 
IP3 CKRDLSRRC HA Ag-NP IV 
*chimeric with linTT1 peptide 
 
 
 
Figure 4. Nanoparticle platforms used in this thesis. Adapted from (Sharma et al., 2017, 
Simon-Gracia et al., 2016a, Braun et al., 2014). 
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4.2.1. TPP-NP preparation 
NWs used in this thesis (publication I) were synthesized using a modified proto-
col adopted from methodology of preparing magnetic Iron oxide (IO) nano-
spheres (NS) based on the reaction of Fe (II) and Fe (III) salts in the presence of 
dextran (Palmacci S., Josephson L., 1993). To generate particles with a worm-
like structure, higher concentrations of Fe-salts and higher MW dextran was 
used in the synthesis. In the last step of the synthesis, dextran coating of the iron 
cores was aminated to allow the attachment of N-hydroxysuccinimidyl (NHS) 
esters during the TPP coupling. Briefly, NHS-PEG-Maleimide linker was used 
to coat the aminated NW surface with malemide goups. Maleimides are electro-
philic compounds that show high selectivity towards thiols present on cysteine 
residues of peptides and proteins. All the TPP used in this work were en-
gineered to contain an extra cysteine residue for maleimide coupling.  
PS used in publications II and III were prepared by self-assembly of amphi-
philic copolymers in water. To label the PS with either 5(6)-carboxyfluorescein 
(FAM) or Rhodamine (Rho), the respective fluorophore was conjugated to the 
polymer during the synthesis. To encapsulate drugs (e.g. hydrophobic pacli-
taxel) inside the vesicles, organic solvents, such as CHCl3 and MeOH, were 
used. The copolymer and the drug were mixed to form complexes. The comple-
xes were dried under vacuum to remove the solvents and the final product-a 
polymer film, was dissolved in PBS. To functionalize the PS with TPPs, 
maleimide-cysteine reaction was used as for the NWs, except that the male-
imide groups were incorporated into the copolymer during synthesis. 
Ag-NPs used in publication IV were loaded with targeting peptides using 
neutravidin-biotin interaction. Neutravidin binds non-covalently with a very 
high affinity to biotin. Ag particles were prepared with neutravidin coating and 
the particles were coated with biotinylated IP3 peptide.  
 
 
4.2.2. Characterization of nanoparticles 
Throughout the current thesis, Dynamic Light Scattering (DLS) was used to 
assess the polydispersity and the average size of the nanoparticles. Transmission 
electron microscopy (TEM) was used to image the nanoparticles.  
 
 
4.3. Bioactivity of TPP-NP in vitro 
 4.3.1. Binding of TPP-NP in a cell-free system (Publications I, II)  
Recombinant hexahistidine–tagged p32 and NRP-1 b1b2 domain were bacte-
rially expressed and purified as described (Paasonen et al., 2016, Teesalu et al., 
2009). For cell-free binding assays, Ni-NTA magnetic agarose beads (Qiagen, 
Germany) in binding buffer (50 mM Tris pH 7.4, 150 mM NaCl, 0.05% NP40, 
5 mM imidazole) were coated with p32 or b1b2 domain of the NRP-1 protein 
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(at 15 µg of protein/10 µL beads). Fluorescently labeled NWs or Rho-labeled 
PS were incubated with the protein coated beads in binding buffer containing 
1% BSA at RT for 1 h. Incubation was followed by washes and elution with 
400 mM imidazole containing binding buffer. The fluorescence of eluted 
samples, either at 490/520 nm with NW samples or at 526/555 nm with Rho-PS 
samples, was quantified using a fluorescence plate reader (FlexStation II, 
Molecular Devices, CA, USA). 
 
 
4.3.2. Cellular binding and internalization of NPs 
For flow cytometry experiments MKN-45P, CT-26, SKOV-3 cells in suspen-
sion were incubated with targeted or non-targeted NWs in complete cell culture 
medium for 1 h. The NW-containing solution was removed, cells were washed 
and analyzed by flow cytometry (Accuri, BD Biosciences, CA, USA). Anti-p32 
antibody inhibition was done by pre-incubating the cells in suspension with 20 
µg/mL of in-house rabbit polyclonal p32 antibody, followed by NW incubation 
for 1 h, washes and flow cytometry.  
For fluorescence confocal imaging of FAM-labeled NWs and PS, MKN-
45P, CT-26, SKOV-3, or PPC-1 cells (all at 5 × 104 cells/well) were seeded on 
glass coverslips in a 24-well plate. After 24 h, NWs (at 40 g Fe/well) or PS (at 
0.5 mg/mL) were added to the cells and incubated at 37 ⁰C for 3 h (NW) or 1 h 
(PS). The cells were washed with PBS, fixed with 4 % of paraformaldehyde 
(PFA) in PBS pH 7.4, co-stained with DAPI and in-house rabbit anti-p32 or 
rabbit anti-NRP-1 antibody (Abcam, UK). Alexa 647-conjugated goat anti-
rabbit IgG was used as a secondary antibody. The samples were imaged with 
fluorescence confocal microscopy (Zeiss LSM 510; Olympus FV1200MPE, 
Germany). 
 
 
4.3.3. Subcellular localization studies 
To study the subcellular localization of NWs, 5 × 104 MKN-45P cells were 
seeded on glass coverslips in a 24-well plate. On next day, the cells were incu-
bated with NWs for 3 h. Subsequently, the cells were fixed and immunostained 
with rabbit anti-fluorescein antibody (cat. no. A889, Thermo Fisher Scientific, 
MA, USA) to detect FAM-labeled NWs and with mouse anti-cytochrome-C 
antibody (cat. no 89918, Thermo Fisher Scientific, MA, USA) to label mito-
chondria. The images were analyzed using the FV10-ASW 4.2 Viewer image 
software (Olympus, Germany).  
To study cellular uptake of the PS samples a total of 5 × 104 PPC-1 cells 
were seeded in a 24-well plate with a coverslip. After 24 h PS loaded with Rho 
or with DOX were added to the cells at a concentration of 0.5 mg/mL and 
incubated for an hour. The cells were washed with PBS, fixed, stained with 
DAPI, and observed under the fluorescence confocal microscopy (Zeiss LSM 
510). 
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4.3.4. Evaluation of nanoparticle cytotoxicity in vitro 
4.3.4.1. MTT colorimetric assay 
Cell viability was assessed by colorimetric assay based on reducing the tetra-
zolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
by NAD(P)H-dependent cellular oxidoreductase to insoluble purple formazan. 
Briefly, cells were seeded in 96-well plates (104 MKN-45P or SKOV-3 cells, 
and 5 × 103 CT-26 cells) and grown in full medium at 37 °C. After 24 h diffe-
rent concentrations of NWs (3, 10, 30, 100, 300 g/mL iron) were added to the 
wells.  
After 6 h the medium was replaced with a fresh medium and after 18 h of 
incubation at 37 °C, the medium was aspirated and 10 μL of 5 mg/mL MTT 
reagent in PBS was added. The MTT reagent was removed in 2 h and the blue 
formazan crystals were dissolved in 100 μL of isopropanol and the absorbance 
was measured at 570 nm with a microplate reader (Tecan Austria, Austria). 
Alternatively, the cells were incubated for 24 h with the samples and the MTT 
assay was performed as described before. 
 
 
4.3.4.2. xCELLigence® Real Time Cell Analysis (RTCA) 
For real time cytotoxicity measurements, we used xCELLigence® RTCA DP 
instrument (Roche Diagnostics, GmbH, Mannheim, Germany and ACEA Bio-
sciences, Inc. San Diego, CA, USA). Experiments were carried out using 
disposable 16-well xCELLigence® E-Plates with microelectrodes attached to the 
bottom of the wells for impedance measurements. To set the baseline, 50 L of 
complete medium was added to the wells and background impedance was mea-
sured for each well. Subsequently, 50 L of complete medium containing 105 
cells was added to each well and E-plates were incubated in the RTCA DP 
device at 37 °C for 24 h. The impedance value was automatically collected in 
every 30 min and expressed as a cell index value (CI). Twenty-four hours after 
cell seeding, different compounds (PS, PS-PTX, RPAR-PS-PTX, iRGD-PS-
PTX, and ABX) were added in triplicate at a final concentration of 100 nM of 
PTX. Complete medium alone was added to the control wells. CI was 
determined every 30 min over the following 25 h. All data were recorded and 
analysed using RTCA software version 1.2.1. CI-data from the experiments was 
normalized to the last data point prior to the addition of compounds. The data 
was expressed as percent viability relative to the untreated cells.  
 
4.3.5. Ex vivo dipping assay on clinical tumor samples 
Fresh surgical samples of peritoneal metastases of colon cancer patients were 
obtained under protocols approved by the Ethics Committee of the University of 
Tartu, Estonia (permit #243/T27).  
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The samples were immediately divided in explants of around 1 cm3 and 
incubated with NWs (40 g/mL Fe), PS (0.5 mg/mL) and AgNPs diluted in 
DMEM containing 1 % of BSA at 37 °C for 4 h. Next, the explants were 
washed 3 times with PBS, snap-frozen, cryosectioned at 10 m, and immuno-
stained using rabbit anti-fluorescein primary antibodies, followed by detection 
with Alexa-546 anti-rabbit secondary antibody (Invitrogen, Thermo Fisher 
Scientific, MA, USA). Alternatively, CF-555 dye labeled Ag-NP were used to 
visualize the tumor homing. 
 
 
4.4. Biodistribution studies of TPP-NP In vivo 
4.4.1. Experimental tumor mice 
For in vivo homing studies nude mice were injected IP with 2 × 106 MKN-45P 
cells or 5 × 106 SKOV-3 cells. Balb/c mice received an IP injection of 2 × 106 
CT-26 cells. Tumors were allowed to develop for 14 days in MKN-45P-injected 
mice and 4 weeks in SKOV-3-injected mice and 7 days in CT-26 injected mice. 
For dual tumors, nude mice were additionally inoculated with 106 MKN-45P or 
0.5 × 106 CT-26 cells subcutaneously (SC) in the right flank. 
 
 
4.4.2. Biodistribution studies of TPP-NP  
To investigate the homing of NWs, the mice bearing MKN-45P, SKOV-3 or 
CT-26 IP tumors were injected IP or IV with FAM-labeled NWs (5 mg/kg Fe) 
and 5 h later the animals were perfused with 10 mL of PBS. After perfusion, the 
tumors and organs were excised, snap-frozen in liquid nitrogen, and stored at -
80 °C for further analysis.  
To test homing of PS, FAM-labeled PS were injected IP (0.5 mg in 500 µL 
of PBS) or IV (0.5 mg in 100 µL of PBS) and after 4 h the animals were 
perfused with 10 mL of PBS. Alternatively, CF-555 dye labeled Ag-NP were 
injected IP into MKN45-P tumor bearing mice and after 4h, animals were 
perfused with PBS. 
After perfusion, the tumors and organs were excised, snap-frozen in liquid 
nitrogen, and stored at -80 °C for further analysis.  
 
 
4.4.3. Ex vivo imaging 
Targeted and non-targeted PS samples were injected into MKN-45P or CT-26 
tumor bearing mice and after 4 h the tumors and organs were excised and 
washed with PBS for fluorescence visualization under Illumatool light source 
using the FAM filter set (Lightools Research, US), image acquisition using a 
digital camera, and fluorescence quantification using Image J software. 
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4.4.4. Magnetic resonance imaging (MRI) 
Nude mice bearing MKN-45P IP tumors were injected IP with NWs coated 
with linTT1 peptide or FAM only (5 mg/kg Fe per injection). The mice were 
subjected to MRI before injection and 5 h after the NW injection. For each scan 
mice were anestesized with isoflurane (3.5% induction, 1.5–2.0% maintenance) 
in air/O2 (2:1) and placed in a MR receiver mouse coil. Fast spin echo T2-
weighted iron sensitive MRI scans were acquired using 9.4 T MR system 
(Bruker, USA) at TR/TE=1.8 s/23 ms and slice thickness of 0.5 mm. 
 
 
4.4.5. In vivo evaluation of bystander activity 
MKN-45P tumor mice were sequentially injected with 5 mg/kg of NWs and  
0.3 mg Texas red-conjugated 70-kDa lysine-fixable dextran (Molecular Probes, 
MA, USA) in PBS into the abdominal cavity (total volume of injection: 1 mL). 
After 90 min, the mice were terminated, and the tissues were excised and 
processed for immunofluorescence. 
 
 
4.5. Immunofluorescence and microscopic imaging 
For immunofluorescence staining of tissues, 10 μm cryosections were equi-
librated at RT, fixed in PFA for 15 min, permeabilized using PBS containing 
0.2% Triton-X for 10 min, and blocked in PBS containing 0.05 % Tween-20,  
5% FBS, 5% BSA, and 5 % goat serum (GE Healthcare, UK) for 1 h. The 
sections were immunostained with rabbit anti-fluorescein (cat. no. A889, 
Thermo Fisher Scientific, MA, USA), rat anti-mouse CD31, biotin rat anti-
mouse CD11b (cat. no. 553370; 557395, BD Biosciences, CA, USA), rat anti-
mouse LYVE-1 (cat. no. 14044382, eBioscience, CA, USA), rabbit polyclonal 
anti-Ki67 (cat. no. NB500-170, Novusbio, UK), and rabbit anti-Cleaved 
Caspase-3 (Asp 175), (cat. no. 966, Cell Signaling Technology, Inc., MA, 
USA), rabbit anti-NRP-1 (Abcam, UK) or rabbit anti-αv-integrin (Millipore, 
US) as primary antibodies. Alexa 488-conjugated goat anti-rabbit IgG, Alexa 
647-conjugated goat anti-rat IgG, Alexa 546-conjugated goat anti-rabbit IgG 
(all Invitrogen, Thermo Fisher Scientific, MA, USA) and streptavidin Dylight® 
550 (Thermo Fisher Scientific, MA, USA) were used as secondary antibodies. 
Nuclei were counterstained with 10 μg/ml DAPI. The stained tissue sections 
were examined by fluorescence confocal microscopy using Olympus 
FV1200MPE or Zeiss LSM 510 instrument, and the images were processed and 
analyzed using the FV10-ASW 4.2 Viewer image software (Olympus, Ger-
many) or ZEN lite 2012 image software and ImageJ freeware. 
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4.6. Experimental tumor therapy  
To test the in vivo efficacy of linTT1 proapoptotic NW, IP MKN-45P tumors 
were induced in nude mice by IP injection of 1.5 × 106 MKN-45P cells in 500 L 
of PBS. Five days after tumor induction, the mice were randomized into 5 groups 
(8 mice in each group). Starting on day 5, mice were IP injected every other day 
with linTT1-NW, D(KLAKLAK)2-NW, linTT1- D(KLAKLAK)2-NWs, or non-
targeted NWs at a dose 5 mg/kg Fe per injection, or with 500 μl of PBS. Body 
weight was monitored daily and the study was terminated when the body weight 
of the first animal in the study decreased by 20 % compared to the start of the 
treatment. The mice were perfused with 10 mL of PBS and larger tumors in the 
IP cavity were weighed and metastatic nodules smaller than 2 mm in diameter 
were counted. 
To investigate the in vivo efficacy of targeted and non-targeted PS the 
athymic nude mice were injected IP with 2 × 106 MKN-45P cells. Three days 
after the cell injection, the mice were randomized in 4 groups (8 animals in each 
group). The mice were treated every other day with IP injections of 0.5 mL of 
ABX, PS-PTX, iRGD-PS-PTX, at the same PTX dose (cumulative dose:  
7 mg/kg), or with PBS. 18 days after tumor induction the mice were perfused 
with 10 mL of PBS and the tumors and organs were excised. To estimate the 
tumor burden, the total weight of large (tumors bigger than 5 mm in diameter) 
and medium peritoneal tumors (tumors bigger than 2 mm and smaller than  
5 mm of diameter) together with the small metastatic peritoneal nodules (tumor 
nodules smaller than 2 mm of diameter) was determined.   
 
 
4.7. Statistical analysis 
Student’s t-test and one-way analysis of variance (ANOVA) with Bonferroni 
comparison tests was performed using GraphPad Prism Software (Graphpad, 
CA, USA). ANOVA and Fisher LSD was performed with Statistica 8 software 
(StatSoft, OK, USA). 
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5. RESULTS 
5.1. TPP-NP show receptor-dependent specificity and 
cytotoxicity in vitro (Publications I–III) 
5.1.1. TPP-NP selectively bind to their target proteins 
To study suitability of RPARPAR and TT1 homing peptides for affinity 
targeting of NPs, we first evaluated the interaction of peptide guided NPs with 
their cognate receptors (NRP-1 and p32, respectively) in a cell-free system. PS 
functionalized with RPARPAR (RPAR-PS) peptide readily bound to im-
mobilized recombinant b1b2 domain of NRP-1 (Fig. 5A). The RPAR-PS 
showed only a background binding to recombinant p32 and untargeted PS did 
not bind to either protein.  
In the case of NWs (Fig. 5B), we observed that fluorescein FAM-labeled 
linTT1-NWs readily bound to immobilized p32, whereas untargeted FAM-
NWs, or FAM-NWs functionalized with a control RPARPAR peptide, showed 
only background binding. 
These data show that homing peptides coated on PS or NWs are available for 
receptor interactions and that the tropism of nanoparticles can be specifically 
modulated by functionalization with TPPs. 
 
 
Figure 5. Binding of peptide-NPs to purified receptor proteins. (A) Binding of 
RPARPAR-PS or PS labeled with rhodamine to recombinant NRP-1 (b1b2 NRP-1) or 
to p32. For this assay, 0.5 mg/mL of PS samples were incubated with the recombinant 
proteins for 1h. Y-axis represents the bound PS fluorescence in arbitrary units (A.U.). 
N=3 (B) Binding of FAM-labeled linTT1-NWs, RPARPAR-NWs or control FAM-NWs 
to recombinant p32. Thirty µg/mL of NWs were incubated with immobilized his-tagged 
p32 for 1 h, followed by washes to remove unbound NWs and quantification of bound 
FAM-NWs by spectrometry. Y-axis represents the bound NW fluorescence in arbitrary 
units (a.u.). N = 3; statistical analysis by one-way ANOVA; error bars, mean + SEM,  
* p ˂ 0.05; ***, p < 0.001. 
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5.1.2. TPP-NP bind to cultured PC cells in  
receptor-dependent manner 
Since the target receptors for homing peptides used in this study, p32 and NRP-
1, are predominantly upregulated on the surface of proliferating malignant cells, 
we established the relevance of p32 for linTT1-NW targeting and NRP-1 for 
RPAR-PS targeting. We determined whether on cultured PC cells plasma 
membrane p32 can be targeted with linTT1-NWs and cell surface NRP-1 can be 
targeted with RPAR-PS and iRGD-PS. To study interaction of linTT1-NW with 
p32-positive cells, we used flow cytometry analysis on non-permeabilized cells. 
The LinTT1-NWs, not FAM-NW, were found associated with the p32-positive 
cells after 1 h incubation. To further verify if the LinTT1-NW binding was p32 
dependent, we pre-incubated the cells prior to incubating with NW samples 
with a function-blocking anti-p32 antibody. The blocking of p32 reduced 
LinTT1-NW binding up to 90 % (Fig. 6A, B). Confocal microscopy of cultured 
cells 3 h after addition of NWs revealed colocalization of linTT1-NW with p32 
on the surface of the MKN-45P, CT-26 and SKOV-3 cells, whereas untargeted 
NW showed minimal binding (Fig. 6C). After 1 h of incubation, RPAR-PS 
showed a high uptake in both cell lines, whereas the control FAM-PS showed a 
low baseline uptake in both cell lines (Fig. 6D). 
These experiments demonstrated that p32 and NRP-1 are expressed on the 
cell surface of cultured PC cell lines and that NP coating with linTT1, iRGD, or 
RPAR peptides can be used for robust and specific targeted delivery of com-
pounds and nanoparticles to PC cells.  
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Figure 6. TPP-NP bind to cultured peritoneal carcinomatosis cells in a receptor 
dependent manner. (A) Flow cytometry of MKN-45P, SKOV-3 and CT-26 cells 
incubated with linTT1-NWs and control FAM-labeled NWs. Cells in suspension were 
incubated with NWs (at 30 µg/mL Fe) for 1h, followed by washes, and flow cytometry 
analysis. Green line: cells incubated with linTT1-NWs; red line: cells incubated with 
NWs; black line: cells without NW incubation. (B) Anti-p32 antibody inhibition of NW 
binding to MKN-45P, SKOV-3 and CT-26 cells. Suspended cells were pre-incubated 
with 20 µg/mL of p32 antibody, followed by NW incubation for 1h, washes and flow 
cytometry. The labeling color scheme is the same as in A. (C) Fluorescence confocal 
imaging of cultured adherent MKN-45P, CT-26 and SKOV-3 cells incubated with 
linTT1-NWs or non-targeted NWs for 3 h. Green: NWs; Red: p32; blue: DAPI. Scale 
bars: 30 µm. (D) Fluorescence confocal imaging of MKN-45P and CT-26 cells 
incubated with 0.5 mg/mL of RPAR-PS (R-PS), iRGD-PS or FAM-PS for 1 h. The cells 
were stained with DAPI and anti-NRP-1 antibody. Green: PS; red: NRP-1; blue: DAPI. 
Scale bars: 20 µm. 
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5.1.3. Internalized linTT1-NW are routed to mitochondria and 
have a cytotoxic effect on cultured IP tumor cells 
In activated cells, p32 is present at the cells surface and in the mitochondria and 
by cycling between those two locations, could take payloads with it (Agemy et 
al., 2013). Thus, mitochondrial localization of linTT1 can be used to improve 
the cytotoxic activity of pro-apoptotic peptide, D(KLAKLAK)2, that exerts its 
effect by destabilization of mitochondrial membranes (Ellerby et al., 1999). We 
hypothesized that linTT1 peptide may be well suited for mitochondrial targeting 
of D(KLAKLAK)2 effector module in the p32-positive PC cells. First, confocal 
imaging of MKN-45P cells demonstrated that after 3 h of incubation intra-
cellular linTT1-NWs colocalized with cytochrome C, a mitochondrial marker 
(Fig. 7A). Next, we studied the effect of NWs coated with linTT1-
D(KLAKLAK)2 chimeric peptide on viability of cultured MKN-45P, CT-26, and 
SKOV-3 cells and found that linTT1-D(KLAKLAK)2-NWs reduced the viability 
of all three PC cell lines, with treatment at the highest concentration, 300 ug 
Fe/mL (~50 nmol/mL peptide) causing death of about 40 % cells (Fig. 7B-D). 
In contrast, control NWs coated with either peptide alone did not have an effect. 
These observations indicate that the linTT1-NW uptake pathway in PC cells is 
compatible with in vitro delivery of mitochondrially-acting proapoptotic peptide 
to induce cell death. 
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Figure 7. LinTT1-NWs are routed to mitochondria and potentiate the activity of a 
proapoptotic peptide payload. (A) Internalized linTT1-NWs colocalize with a 
mitochondrial marker, cytochrome C. MKN-45P cells were incubated with linTT1-NWs 
for 3 h, washed, and fixed for immunofluorescence staining. The cells were incubated 
with rabbit anti-FITC primary antibody to detect the NWs and with mouse anti-
cytochrome C to label mitochondria, followed by incubation with anti-mouse Alexa 
Fluor-546 and anti-rabbit Alexa Fluor 647 secondary antibodies; nuclei stained with 
DAPI. linTT1-NW: green; cytochrome C (Cyt-C): red; DAPI: blue; colocalization of 
FAM and Cyt-C signal: white. Scale bar: 5 m. (B-D) Treatment with linTT1-NW 
coupled to the proapoptotic peptide D(KLAKLAK)2, decreases viability of tumor cells. 
MKN-45P, CT-26 and SKOV-3 cells were incubated with the indicated NWs over a 
range of iron concentrations (3, 10, 30, 100, 300 µg/mL), and cell viability was assessed 
after 6 h incubation by a colorimetric assay based on reducing the tetrazolium dye MTT. 
KL: D(KLAKLAK)2. Statistical analysis was performed by ANOVA. n=3; error bars 
indicate ±SEM; *** p ˂ 0.001, ** p ˂ 0.01, * p ˂ 0.05. 
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5.1.4. TPP-PS release their cytotoxic cargo in the  
cytoplasm to exert time dependent cytotoxicity on target cells 
Following cellular uptake via endosomal internalization pathway, PS cargo is 
released into the cytoplasm, possibly through endosomal membrane disruption 
by proton sponge effect (Massignani et al., 2009). We loaded RPAR-PS with 
fluorescent cargoes [Rhodamine B octadecyl ester (Rho) and Doxorubicin 
(DOX)] to study the in vitro internalization in PPC-1 cells and cytoplasmic 
release of cargo from peptide -guided PS. After 1-h incubation of PPC-1 cells 
with RPAR-FAM-PS loaded with Rho, a widespread Rho fluorescence was 
observed in the cytoplasm (Fig. 8A). Interestingly, already 1 h after incubation 
with the cells, the FAM-RPAR-polymer and Rho cargo exhibited clearly diffe-
rent intracellular distribution patterns (arrow in Fig. 8A). After 1 h incubation of 
PPC-1 cells with the DOX-loaded RPAR-PS, the intrinsic red fluorescence of 
DOX was observed in the nuclei of the cells (arrow in Fig. 8B). In contrast, 
only a weak DOX signal was seen in PPC-1 cells incubated in the presence of 
DOX-loaded untargeted PS (Fig. 8B). These data suggest that cellular uptake of 
TPP-PS is followed by disassembly of PS and cytoplasmic release of the 
payloads.  
Next, we determined the cytotoxicity profile of TPP-PS loaded with cyto-
toxic drug, paclitaxel (PTX). As a reference, we used Abraxane (ABX), a 
colloidal suspension of paclitaxel and human serum albumin that is clinically 
approved for the treatment of several types of solid tumors (breast, lung, 
pancreatic, and gastric carcinoma), and is in advanced clinical trials for the 
treatment of colorectal cancer. We studied the viability of NRP-1-positive PPC-
1 and NRP-1-negative M21 cells using xCELLigence RTCA DP technology – a 
real-time label-free technique to assess cellular proliferation, migration and 
invasion of cultured cells. We exposed cells to different compounds all at 100 
nM PTX. In PPC-1 cells, PTX-PS targeted with RPAR and iRGD peptides were 
significantly more toxic than untargeted PTX-PS, or ABX (Fig. 8C). Approxi-
mately 50% of PPC-1 cells treated with RPAR-targeted or iRGD-targeted PTX-
PS remained viable after 24 h of incubation, whereas about 80% of cells treated 
with untargeted PTX-PS were viable, and ABX had only a negligible effect 
(Fig. 8C). When observing NRP-1 negative M21 cells, the viability was not 
significantly affected by 24-h exposure to PTX-loaded PS targeted with iRGD 
or RPAR (Fig. 8C). Empty PS did not affect cell viability at any time point 
tested. These experiments show that PTX-PS targeted with TPP specifically 
decrease the viability of cultured NRP-1 expressing cells. 
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Figure 8. Peptide-guided PS release their cargo in the cytoplasm of target cells and 
potentiate the activity of an anticancer payload. (A) Fluorescence confocal imaging of 
PPC-1 cells incubated with 0.5 mg/mL of RPAR-FAM-PS loaded with Rho for 1 h. The 
cells were counterstained with DAPI. Green: PS; red: Rho; blue: DAPI. Scale bar: 20 µm. 
Representative fields from multiple areas of cultured cells from three independent experi-
ments are shown. (B) Fluorescence confocal imaging of PPC-1 cells incubated with 0.5 
mg/mL of RPAR-PS or PS loaded with doxorubicin (DOX) for 1 h. The cells were stained 
with DAPI. Green: NRP-1; red: DOX; blue: DAPI. Scale bars: 20 µm. Representative 
fields from multiple areas of cultured cells from three independent experiments are shown. 
(C) Growth rate dynamics of cultured PPC-1 and M21 cells after addition of the RPAR, 
iRGD, or untargeted PS loaded with PTX, and ABX at 100 µM PTX concentration, mea-
sured using the xCELLigence® real-time cell analyzer that allows continuous quantitative 
monitoring of attached cells. 100 % viability corresponds to untreated cells. N=3. Error 
bars: mean ±SEM. 
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5.2. TPP-NP home selectively to tumor lesions ex vivo and  
in vivo (Publications I–IV) 
5.2.1. TPP-NP home to clinical tumor explants ex vivo 
To evaluate the translational potential of TPP-NP we tested the binding of NW, 
PS and AgNP coupled with different tumor homing peptides on fresh surgical 
explants of peritoneal metastasis of human colon cancer. The ex vivo tumor 
dipping assay results showed TPP-NP binding in human colon cancer tissues, 
whereas the control NP only weakly labeled the surface of the tumors (Fig. 9). 
These findings serve as an initial starting point towards the translation of the 
TPP-NP platforms into clinical setting. 
 
 
Figure 9. Confocal fluorescence microscopy imaging of TPP-NW binding to human 
colon cancer explants. Fresh surgical samples of colon cancer were incubated with 
targeted NPs or untargeted NPs for 4 h at 37 °C, followed by sectioning and staining 
with anti-FITC (rabbit) and Alexa Fluor 546 (anti-rabbit) secondary antibody. Alter-
natively, CF-555 dye labeled Ag-NP were used to visualize the homing of the IP3-
labeled AgNP. Arrows point to IP3-AgNP bound to the edge of the tumor. Red: NPs; 
blue: DAPI. Scale bars: 200 µm. 
 
5.2.2. Intraperitoneally-injected linTT1-NW have  
improved tumor selectivity over systemically-injected NWs 
We next studied the biodistribution and accumulation of linTT1-NW in tumor 
tissue and control organs by comparing two administration routes: systemic IV 
injection and locoregional IP injection. For that we used MKN-45P peritoneal 
tumors in mice. Five h after IP injection of linTT1-NW, we observed wide-
spread signal in the tumor tissue and low background in the control organs (Fig. 
10B). In contrast, tumor signal in mice injected with systemic linTT1-NW was 
accompanied by a strong non-specific background in control organs, 
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particularly in the liver (Fig. 10A, B). Quantitative imaging of the mice dosed 
IP or IV with linTT1-NWs showed that the FAM signal in the tumors was 
almost twice as high after IP injection, whereas the signal in control tissues was 
more than 3-fold lower after IP administration (Fig. 10C) further supporting the 
superiority of IP administration route for peptide NWs for PC targeting. 
 
 
 
Figure 10. Intraperitoneal linTT1-NWs have improved tumor selectivity over syste-
mically administered NWs. (A) Representative fluorescence confocal images of linTT1-
NW at 5 h after IP (first column) or IV injection (second column) demonstrate tumor 
homing for both routes of administration. Cryosections of tumor tissues were stained 
with a CD31 antibody to visualize the blood vessels. Green: NWs; Red: CD31, Blue: 
DAPI. Representative fields from multiple sections (n ≥3) prepared from at least 3 
tumors are shown. Scale bars: 100 µm. (B) Biodistribution of linTT1-NWs injected IP 
or IV in non-target organs (liver and kidney) in mice bearing MKN-45P tumors. NWs 
were injected at a dose of 5 mg/kg, and tissues were collected after 5 h. Blue, DAPI; 
green: FAM. Scale bars: 100 µm. (C) Quantification of green fluorescence in tumor, 
liver and kidney after IP or IV injection of linTT1-NWs. Fluorescence signal intensity 
was quantified by ImageJ freeware and normalized for tissue area. Representative fields 
from multiple sections from tumors in 3 mice are shown. 
 
5.2.3. LinTT1-NW home to peritoneal tumor lesions in vivo 
Immunophenotyping of cells positive for linTT1-NWs with a panel of cell type 
specific marker antibodies demonstrated that in MKN-45P tumor model linTT1-
NWs co-localized with CD31-positive blood vessels (Fig. 11A, B). Outside tumor 
blood vessels, a partial overlap was seen with lymphatic vessels and macrophages 
(Fig. 11). Similar pattern was observed in SKOV-3 ovarian tumor tissue where 
linTT1-NW co-localized with blood vessels and macrophages (Fig. 11), 
suggesting that a combination of direct penetration from the IP cavity and indirect 
accumulation via systemic circulation drives tumor accumulation of the linTT1-
NWs. In the case of CT-26 tumors, we observed near-complete colocalization of 
linTT1-NWs with CD11b-positive macrophages (Fig. 11) suggesting that in this 
model particle accumulation is primarily direct, not vascular-mediated.  
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The distinct localization pattern in different types of tumor tissue can be sup-
ported by previous data that cell surface p32 is expressed besides tumor cells 
also on other activated cells such as vascular and lymphatic endothelial cells 
and tumor-associated macrophages, especially in hypoxic and nutrient-deprived 
areas (Fogal et al., 2008, Agemy et al., 2013) and that p32 expression level and 
subcellular localization has also been demonstrated to be affected by the tumor 
type and -stage. 
 
 
 
 
Figure 11. Characterization of LinTT1-NW target cell populations in different models 
of peritoneal carcinomatosis. (A) Confocal imaging of tumor sections. Mice bearing 
MKN-45P (upper panel), CT-26 (middle panel) and SKOV-3 (lower panel) tumors were 
IP injected with linTT1-NWs (5mg iron/kg). Tissues were collected after 5 h circula-
tion, and cryosections of tumor tissue were stained with antibodies against CD31 (blood 
vessels), LYVE-1 (lymphatic vessels) and CD11b (macrophages). Green: NWs; Red: 
CD31, LYVE-1 or CD11b. Blue: DAPI. Scale bars: 100 µm. (B) Colocalization ana-
lysis of linTT1-NWs with CD31, LYVE-1 and CD11b in MKN-45P, CT-26 and 
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SKOV-3 tumor models based on Manders (M) coefficient (Manders, Verbeek & Aten, 
1993) 0= no colocalization; 1= complete colocalization. Analysis was performed by 
ImageJ software. Error bars, mean ±SEM (C) Quantification of green fluorescence 
intensity in the confocal images of tissue sections prepared from MKN-45P, CT-26 and 
SKOV-3 tumors. Representative fields from multiple sections of tumors from 3 mice 
per group are shown. Analysis by ImageJ, N ≥ 3 mice; Statistical analysis: Student’s t-
test; error bars: mean ± SEM; **p < 0.01, *p < 0.05.  
 
5.2.4. LinTT1-NWs as a tumor-seeking contrast agent 
Iron oxide is a well-known imaging agent that produces hypointense areas in 
T2-weighted MR images (McAteer et al., 2007). To investigate the potential of 
linTT1-NWs for PC imaging we performed MR imaging experiments. Nude 
mice bearing MKN-45P IP tumors were injected with linTT1-coated or control 
NW. The tumor areas in mice injected with TT1-NW showed hypointense re-
gions, whereas untargeted NW produced no detectable signal decrease under the 
same imaging conditions (Fig. 12A and B). Post- MRI ex vivo imaging of 
tumors and control organs showed selective accumulation of fluorescently 
labeled TT1-NW in tumor tissue (Fig. 12C). 
 
 
 
Figure 12. PC imaging with linTT1-NWs. (A) T2-weighted magnetic resonance images 
of mice bearing IP MKN-45P tumors. The mice were injected intraperitoneally with 
linTT1-coated or control FAM-coated NWs (5 mg/ kg of iron). (A) Coronal images of 
the tumors were acquired using 9.4 T Bruker MR system (TR/TE=1.8 s/23 ms; slice 
thickness 0.5 mm) before NW injection (pre-scan) and 5 h after NW injection (post 
scan). T, tumor; M, muscle (B) linTT1-NWs produced significant hypointensities in the 
tumor tissue whereas control NWs gave no signal. The signal intensity was normalized 
to the adjacent muscle tissue. Five images per time point were analyzed. Statistical 
analysis: Student’s t-test; error bars: mean + SEM; ** p ˂ 0.01. (C) (C) After MR 
imaging, tumors and control tissues were excised and fluorescent signal was imaged ex 
vivo by Illumatool (Lightools Research, CA). 
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5.2.5. LinTT1-NW trigger bystander effect after IP injection 
LinTT1 belongs to the family of CendR peptides and a relevant feature of these 
peptides is to induce a bystander effect, an increased accumulation of coad-
ministered compounds. For example, the prototypic CendR peptide iRGD in-
creases the accumulation of coadministered payloads in tumor tissue (Schmithals 
et al., 2015, Deng et al., 2017). To determine whether linTT1 coupled to NW 
could trigger a trans-tissue transport pathway for coadministered payloads 
(Sugahara et al., 2010), we administered via IP injection linTT1 peptide coupled 
to NW (or iRGD-NWs as a positive control) simultaneously with 70 kDa 
fluorescently-labeled dextran, collected the tissues 90 min later, and studied the 
biodistribution of the dextran in tissue sections. We observed a significant 
increase in dextran accumulation in the tumor with linTT1-NWs and iRGD-
NWs, whereas only a minimal signal was present when dextran was injected 
alone (Fig. 13). 
 
 
           
 
Figure 13. IP linTT1-NWs increase MKN-45P tumor accumulation of coadministered 
70 kDa dextran. Mice bearing disseminated MKN-45P tumors were injected IP with the 
indicated NW formulations (5 mg/kg Fe) and 0.3 mg of 70 kD dextran in 1 ml PBS. 
After 90 min, the mice were perfused, and tissues processed for confocal imaging. Red: 
dextran, green: TPP-NP. 
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5.2.6. Conjugation of TPP to the surface of PS  
         improves tumor accumulation after IP injection 
To determine the targeting effect of iRGD or RPAR-PS in a mouse model of PC, 
we studied the homing of IP-administered PS to peritoneal and subcutaneous 
MKN-45P and CT-26 tumors in mice. Macroscopic imaging of tissues after 4 h of 
IP injection demonstrated that FAM-labeled targeted PS accumulated in both 
MKN-45P and CT-26 peritoneal tumors, but not in control organs, whereas 
untargeted FAM-PS gave a weaker tumor signal (Fig. 14A and B). In both tumor 
models, iRGD-PS group showed highest fluorescence in IP tumors and only 
background signal was detected in the control organs (Fig. 14C and D).  
 
 
Figure 14. In vivo biodistribution of IP-administered PS. (A) Mice bearing dual IP and 
SC MKN-45P or CT-26 tumors were IP injected with 0.5 mg of FAM-labeled iRGD-
PS, RPAR-PS, or untargeted PS, and after 4 h the tumors and organs of interest were 
excised and fluorescent signal was imaged by Illumatool (Lightools Research, CA). 
Representative compound fluorescent and bright-field images from three independent 
experiments are shown. He, heart; Lu, lung; Sp, pleen; Ki, kidney; Li, liver; Br, brain, 
Tu, tumor. (B) Quantification of the fluorescent signal in tumors and control organs by 
the ImageJ software. N ≥ 3 mice; statistical analysis was performed by one-way 
ANOVA; error bars, mean + SEM; *** p ˂ 0.001, ** p ˂ 0.01, * p ˂ 0.05. 
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5.2.7.  IP-administered TPP-PS home to peritoneal  
and subcutaneous tumors 
To obtain information on the distribution of the FAM-labeled PS, we immuno-
stained the tissue sections with anti-FAM antibody. In peritoneal MKN-45P 
tumors, iRGD-PS accumulation was seen in the tumor periphery and deep 
within the tumor mass (Fig. 15B, arrows), partially co-localizing with αv-
integrins and NRP-1 (Fig. 15A). In IP CT-26 tumors iRGD-PS accumulated 
predominantly in the tumor periphery (Fig. 15C and D). In SC MKN-45P 
tumors, iRGD-PS were found scattered in the tumor parenchyma, partially over-
lapping with CD31-positive blood vessels (Fig. 15B). In both models, un-
targeted PS only weakly labeled the surface of the peritoneal tumors (Fig. 15B 
and D, arrowhead). The extent iRGD-PS accumulation was lower in the SC CT-
26 than in MKN-45P tumors (Fig. 15B and D). This result correlated with the 
expression of NRP-1, which was lower in the CT-26 tumors (Fig. 15A and C). 
These data indicate that iRGD-functionalization improves the accumulation of 
PS in IP and, to some extent, in SC tumors. 
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Figure 15. Confocal imaging of PS in tumor tissue. Co-localization of FAM-labeled 
iRGD-PS with αv-integrins and NRP-1. (A-D) Fluorescence confocal images of tissue 
sections prepared from IP and SC MKN-45P and CT-26 tumors collected 4 h after IP 
injection of PS. iRGD-FAM-PS and control FAM-PS (0.5 mg) were IP-injected and the 
tumors were excised 4 h later. (A, C) Tissue sections were stained for αv-integrins, or 
NRP-1 (red) (B, D) Tissue sections were stained for blood vessels: CD31 (red) and the 
nuclei were counterstained with DAPI (blue). The green fluorescence corresponds to 
PS, which were labeled with FAM. Scale bar: 200 µm. Representative images of three 
independent experiments are shown. Arrows point to PS co-localizing with blood 
vessels; arrowheads point to PS in tumor periphery.  
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5.2.8. IP-administered IP3 peptide-conjugated AgNPs home 
peritoneal gastric and colon carcinomas (Publication IV) 
IP3 peptide was discovered using a T7 peptide phage library that was IP in-
jected into a MKN-45P tumor bearing mice. The library consisted of cyclic 
peptides with seven random amino acids; CX7C and with a diversity of 108. The 
biopanning combined ex vivo and in vivo selection rounds. Subsequently, the 
peptide-encoding portion of the phage genome was subjected to High Through-
put Sequencing (HTS) with Ion Torrent and analyzed with bioinformatics tools 
for peptide identification. During analysis critical parameter for peptide selec-
tion was high tumor-to-kidney ratio and based on the results IP3 was selected 
for individual evaluation. IP3 peptide contains a hyaluronic acid (HA) binding 
motif and targets tumor extracellular matrix and macrophage rich regions in 
tumors.  
We further assessed whether IP3 has potential as a targeting ligand for NPs, 
biotinylated IP3 and control peptides were coated on ~30 nm silver NPs 
(AgNPs). Peptide-functionalized AgNPs were injected IP into mice bearing 
MKN-45P and CT-26 tumors. Confocal images revealed a robust accumulation 
of IP3-AgNPs in the outer rim of both MKN-45P and CT-26 tumors. In addition 
to the peripheral accumulation, IP3-AgNPs penetrated deeper in the tumor 
(arrows in Fig. 16A, B). In contrast to IP3-AgNPs, only low, background levels 
of the control AgNPs (biotin AgNA555) were observed at the edge of both 
MKN-45P and CT-26 tumors (arrowheads in Fig. 16C, D).  
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Figure 16. IP-administered IP3 peptide-conjugated AgNPs home to peritoneal gastric 
and colon carcinomas. Confocal imaging of MKN-45P and CT-26 tumors after 4 h of 
injection with AgNPs (red). The cryosections were immunostained anti-CD31 (green) 
and the nuclei were counterstained with DAPI (blue). (A, B) Tumor homing and 
penetration of IP3-AgNPs. (A) IP3-AgNPs located away from the edge of the tumor to 
some degree while being in close proximity to blood vessels or without association with 
blood vessels (arrows in Figure 4A). (B) IP3-AgNPs were found associated with blood 
vessels and accumulated in the avascular regions. Arrows point to IP3-AgNPs in the 
avascular region. Inset in B: IP3-AgNPs overlapped with blood vessels inside the tumor 
(arrows). (C, D) Imaging of control nanoparticles. The control AgNPs located on the 
edge of the tumor for both MKN-45P (C) and CT-26 tumors (D) (arrows). (A-D): Red, 
AgNPs; green, CD31; blue, DAPI. Scale bar: 200 m; inset in B: 100 m. 
 
 
  
57 
5.3. TPP functionalization enhances therapeutic efficacy of 
NPs (Publications I–III) 
5.3.1. TPP functionalization enhances therapeutic efficacy of  
PS-PTX and proapoptotic NW in mouse models of PC 
Based on preferential accumulation of TPP-NP in vitro and having established 
selective tumor targeting in vivo, we evaluated the therapeutic efficacy of PTX-
loaded iRGD-PS and pro-apoptotic linTT1-NW in a mouse model of PC. 
 
 
 
 
Figure 17. Experimental therapy of mice bearing peritoneal MKN-45P tumors. (A, B) 
Experimental treatment results from TPP-PS study. Mice bearing disseminated perito-
neal MKN-45P tumors were injected IP every other day during two weeks with 
indicated formulations (cumulative dose of the treatment: 7 mg PTX/kg). The tumor 
weight (weight of large peritoneal tumors combined with small peritoneal tumor 
nodules) and number of peritoneal tumor nodules after treatment are shown. (C, D) 
Experimental treatment results from TPP-NW study. Mice bearing disseminated IP 
MKN-45P tumors were injected IP every other day during two weeks with the indicated 
NW formulations (5 mg/kg Fe). (B) Total tumor weight and number of peritoneal tumor 
nodules after treatment are shown. KL: D(KLAKLAK)2 apoptotic peptide coupled to 
NWs. N=8 mice in each group. Statistical analysis was performed by one-way 
ANOVA; error bars, mean +SEM; *** p ˂ 0.001. **p < 0.01, *p < 0.05. 
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First, we tested the efficacy of targeted PTX-loaded iRGD-PS in mice bearing 
MKN-45P disseminated IP tumors. Mice were treated with iRGD-PS-PTX, 
untargeted PS-PTX, or ABX, all at the cumulative PTX dose of 7 mg/kg. 
Among the formulations used, iRGD-PS-PTX gave the strongest antitumor 
response. The total weight of all the detectable peritoneal tumors treated with 
iRGD-PS-PTX was significantly lower than those in the ABX and untreated 
groups (Fig. 17A, B). Importantly, treatment with iRGD-PS-PTX also reduced 
the number of peritoneal MKN-45P tumor nodules significantly more effecti-
vely than the other treatments (Fig. 17A, B).  
Since the MKN-45P tumor model in nude mice is well established and 
studied in our lab, we evaluated the therapeutic effect of targeted pro-apoptotic 
linTT1-NW in MKN-45P tumor bearing mice as well. The treatment with 
linTT1-D(KLAKLAK)2-NWs resulted in a significant decrease in tumor burden 
(weight of peritoneal malignant tissue) and in significant reduction in the 
number of tumor nodules (Fig. 17C and D). The control NW treatments did not 
differ from the vehicle control.  
The biggest challenge in the treatment of PC is local dissemination and 
microscopic metastasis. Though visible tumor and metastatic nodules can be 
surgically removed, microscopic metastasis remains, producing recurrence of 
the tumor. In both treatment studies, TPP-PS treated, and TPP-NW treated, we 
detected significantly lower number of tumor nodules in the peptide targeted NP 
group compared to other treatment groups (Fig. 17B, D) These data suggest that 
functionalizing nanoparticles with either iRGD or linTT1 peptide can have a 
significant reducing effect and antitumor activity on metastatic spread in PC. 
 
 
 
  
59 
6. DISCUSSION 
6.1. Significance 
The development of novel strategies to treat peritoneal malignancies is a high 
priority as there is no effective cure. Intraperitoneal (IP) chemotherapy is in-
creasingly used to treat peritoneally disseminated tumors, however the metho-
dology is complex and the effect on antitumor efficacy is modest. The field is 
rapidly advancing by numerous preclinical and clinical studies. For example, 
compared to free chemotherapeutic drugs, IP-administered therapeutic nano-
formulations have superior pharmacokinetic and biodistribution profiles (Dak-
war et al., 2017) and at least two paclitaxel-containing nanoformulations (Nano-
tax® and Abraxane®) are currently under evaluation for PC in clinical trials 
(Williamson et al., 2015, Cristea et al., 2015).  
The work presented in this thesis explored the preclinical application of IP 
administration route for TPP-guided therapeutic nanoparticles to peritoneally 
disseminated tumors. Our studies show that precision-guided locoregional 
delivery can be used to improve efficacy of different classes of NPs loaded with 
anticancer compounds.  
The discovery of novel approaches to treat IP tumors is translationally 
relevant. In our studies we used established clinically relevant tumor models 
and validated the tumor selectivity of the peptide coated particles using fresh 
clinical explants from PC patients. Follow up clinical studies will determine the 
applicability of the TPP-mediated affinity targeting for IP chemotherapy. 
 
 
6.2. Main findings 
Our study was designed to preclinically evaluate the effect of TPP-mediated 
affinity targeting on tumor accumulation and antitumor efficacy of IP-
administered NPs. We found that TPPs increase selectivity of NPs towards PC 
lesions and that this selectivity translates for therapeutic NPs in improved 
efficacy. Our studies also show that increased residence time in the IP cavity 
was achieved for IP-administered NP which enables potentiated direct 
penetration (as opposed to circulation-mediated delivery) of the particles from 
the IP space.  
 
 
6.2.1. LinTT1 functionalization increases tumor selectivity of  
IP injected NPs 
The p32 protein is a well-validated target molecule for systemic treatment of 
tumors (Sharma et al., 2017, Agemy et al., 2011, Karmali et al., 2009), but prior 
to our studies it was not evaluated for IP affinity targeting of PC. We show that 
a number of cell lines representing PC tumors express cell surface p32 at levels 
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relevant for peptide-based tumor affinity targeting. The binding of linTT1-
coated NPs to surface p32 of these cells resulted in cellular internalization into 
p32-expressing PC cell lines in vitro and in tumor accumulation in vivo. 
Importantly, the internalized NPs were found associated with the mitochondria, 
as has been shown previously for a related p32-targeted peptide (Agemy et al., 
2010). 
Coating of NWs with linTT1 peptide potentiated their tumor selectivity and 
anti-tumor activity upon IP administration in p32-dependent manner. In several 
mouse models of PC and fresh clinical tumor explants linTT1-NWs showed 
efficient accumulation that was not present in the case of untargeted NWs. 
These observations warrant follow-up pre-clinical and clinical studies to 
validate the system for the IP treatment of PC.  
 
   
6.2.2. iRGD peptide conjugation potentiates  
IP tumor delivery of PTX-PS 
Our study was the first to show that PS are effective in IP drug delivery. We 
demonstrated that PS loaded with cytotoxic drug Paclitaxel exhibit an intrinsic 
selectivity towards IP tumor lesions by efficiently delivering payloads into 
tumor cells in mouse models of PC in vitro and in vivo. Importantly, we show in 
a mouse model of PC that Paclitaxel-PS have a superior efficacy at a very low 
drug concentration. The PS target peritoneal tumors through a combination of 
direct local penetration and indirect homing via the circulation. This enhanced 
tissue penetration can be attributed to PS being flexible and able to pass through 
pores much smaller than their size (Pegoraro et al., 2014). After demonstrating 
the efficacy of the non-targeted PS in PC we show that by affinity targeting of 
IP administered PS-PTX with TPPs RPARPAR and iRGD that their tumor 
selectivity and antitumor activity can be increased. As the experiments with 
non-targeted PS show a combination of direct and vascular-mediated tumor 
accumulation then by functionalizing the PS surface with iRGD the tumor 
accumulation can be further increased. An explanation can be that whereas the 
iRGD-PS actively penetrated the tumors through a CendR motif-driven tissue 
transcytosis process, the untargeted PS accumulated passively in the periphery 
of the tumors. We determined in an experimental treatment study that PTX-
loaded PS have better antitumor efficacy than PTX or Abraxane, and that con-
jugation of iRGD to PTX-PS renders them even more effective against PC. 
 
 
6.2.3. TPP as ligands for efficient targeting of PC 
Tumor penetrating peptides used in this thesis, linTT1 and iRGD, are both 
characterized by the presence of cryptic R/KXXR/K C-end Rule (CendR) motif 
(iRGD: CRGDKGPDC, linTT1: AKRGARSTA). To be activated, this motif 
requires proteolytic cleavage to activate NRP-1 binding to trigger the CendR 
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cell- and tissue penetration pathway (Teesalu, Sugahara & Ruoslahti, 2013). For 
initial tumor recruitment iRGD and linTT1 use different receptors:  LinTT1 
binds to cell surface p32 – a mitochondrial protein aberrantly displayed on the 
surface of activated tumor cells and cells in tumor stroma (macrophages, 
lymphatic endothelial cells, endothelial cells) (Paasonen et al., 2016) and iRGD 
recognizes integrins upregulated on angiogenic endothelial cells and tumor cells 
(Sugahara et al., 2009). Therefore, linTT1 and iRGD have different targeting 
specificities in the tumor environment. Since tumors can be heterogenous in 
their molecular patterns, the peptides can be used as personalized targeting 
ligands based on specific molecular profile of an individual tumor or used in 
combination for synergistic targeting of the PC. 
 
 
6.2.4. Hyaluronan targeting peptide  
as a targeting ligand in PC 
Hyaluronic acid (HA) is a glycosaminoglycan component of the extracellular 
matrix and distributed widely in epithelial, connective and neural tissues. In 
peritoneal space, HA is present in mesothelial surface, and is upregulated in 
peritoneal tumors of gastrointestinal (Ikemoto et al., 2017) and ovarian origin, 
where it is known to facilitate the peritoneal dissemination (Ween, Oehler & 
Ricciardelli, 2011). The IP3 peptide contains a hyaluronan-binding motif and 
was found to target IP tumors. After IP injection of AgNP coated with IP3 
peptide as a targeting ligand, we saw tumor specific accumulation of IP3-AgNP 
in peritoneal tumors of gastric and colon origin. HA is an abundant target in 
solid tumors and may provide a high capacity target for affinity targeting of 
solid tumors. These data suggest that IP3 peptide has the potential to guide 
drugs, nanoparticles and imaging agents to extracellular matrix of peritoneal 
tumors. 
 
6.2.5. TPP-NPs accumulate in avascular tumor  
        nodules and are effective against micrometastasis 
Clinically the biggest challenge in PC is the peritoneal seeding of tumor. Ava-
scular tumor nodules are largely inaccessible for systemic chemodrugs and 
locally-administered anticancer drugs might not exhibit sufficiently long 
retention time in the IP cavity to penetrate and effectively destroy the remaining 
tumor cells. Our experimental treatment study using TPP-NP on a gastric cancer 
model showed a significant decrease in the number of tumor nodules found in 
the peritoneal cavity thus pointing to effective therapeutic effect on metastatic 
spread in PC. 
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6.3. Future directions 
It has been a century since Paul Ehrlich introduced the concept of “magic 
bullet” – an entity capable of recognizing a specific target to provide a thera-
peutic action at the desired site (Ehrlich, 1908).  Modern version of the magic 
bullet engages different carefully fitted components: 1. A potent drug payload; 
2. A high-capacity nanocarrier; 3. A targeting moiety capable of directing the 
drug-loaded carriers to the target site. This concept is a basis of the design of 
novel smart anticancer therapies (Fornaguera, Garcia-Celma, 2017) and is 
actively explored for locoregional targeting of intraperitoneal tumors (Dakwar 
et al., 2017, Van Oudheusden et al., 2015).  
Personalized medicine applies precision treatments for patient or patient 
groups by considering their genetic and phenotypic factors for optimal 
therapeutic response (Zhang et al., 2012). Image-guided personalized therapies 
can provide critical information on the specific biomarkers /molecular profiles 
and allow design/application of nanosystems based on the presence of affinity 
ligand target molecules in a specific patient cohort (Man, Lammers & T M de 
Rosales, 2018). IP tumors can be extremely heterogenous and it is clear that no 
single treatment can provide a successful cure for all. The versatility at the 
nanoparticle drugs and imaging agents enables a variety of specifically tuned 
treatment modalities.  
Currently marketed nanoproducts represent the first generation nano-
particles. They lack targeting molecules and mainly rely on the EPR effect to 
passively reach the tumor site (e.g Doxil) (Hare et al., 2017, Shi et al., 2017). 
The second generation of nanosystems is defined by having a targeting ligand 
on their surface (e.g a monoclonal antibody) and they are yet to be clinically 
approved. At the moment four polymeric NP loaded with a chemotherapeutic 
drug and coated with HER2 (human epidermal growth factor); EGFR (epi-
dermal growth factor); PSMA (prostate specific membrane antigen) and TfR 
(transferrin receptor) are being evaluated in clinical trials (Shi et al., 2017). 
IP therapies of PC are particularly well suited for nanotherapies. The IP 
administered NPs increase in retention time of the drug in the tumor proximity 
and the IP administered nanocarriers are not subject to nonselective uptake in 
the organs of reticuloendothelial system. Our work showing that affinity 
targeted IP NP have improved tumor selectivity and penetration provide a solid 
rationale for follow up translational studies on improved PC nanotherapies.   
The goal is to support the translation of pre-clinical results to pharmaceutical 
industry and to commercialize the novel nanomedicinal drug products. 
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7. CONCLUSIONS 
1. TPPs: LinTT1, iRGD and RPARPAR coated onto NPs are available for 
receptor interactions and therefore, can be used to selectively target NPs to 
p32 and NRP-1 expressing cultured cells. IP3 peptide allows targeting of the 
HA (Hyaluronic acid) in tumor extracellular matrix. 
2.  Internalized linTT1-NWs are routed to mitochondria and have a cytotoxic 
effect on different IP tumor cell lines. TPP-PS release their cargo in the 
cytoplasm and show cytotoxicity on malignant cells.  
3.  IP injected TPP-NPs have improved IP tumor selectivity over IV injected 
TPP-NPs. After IP injection TPP-NPs are specifically taken up and accu-
mulate in peritoneal tumor lesions using both direct penetration and systemic 
circulation. Tumor accumulation of the NP can be improved by targeting 
with TPPs where TPP-NP homed to and penetrated through peritoneal 
tumors, whereas untargeted NP accumulated only in the tumor periphery. 
4.  Our data show that TPP functionalization enhances therapeutic efficacy of 
PS-PTX and proapoptotic NW in mouse models of PC as significantly lower 
number of metastatic nodules were detected in the treatment group compared 
to the control groups. 
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8. SUMMARY IN ESTONIAN 
Intraperitoneaalsete kasvajate sihtmärgistatud ravi kasutades 
peptiididega suunatud nanoosakesi 
Seedetrakti ja günekoloogiliste pahaloomuliste kasvajate puhul on kasvaja-
rakkude levik kõhuõõnes ehk peritoneaalne kartsinomatoos (PK) üks sagedase-
maid ilminguid. PK haigete keskmine elulemus on 4 kuud. PK ravivõimalused 
on piiratud, kuna süsteemne keemiaravi on madala efektiivsusega ning pat-
siendile manustatavat ravimidoosi piiravad kõrvalnähud kõhuõõnevälistes kude-
des. Võrreldes intravenoossete ravimitega saavutavad otse kõhuõõnde manus-
tatud vähiravimid kasvajakoes kõrgema kontsentratsiooni ning on oluliselt 
efektiivsemad. Sellegipoolest põhjustavad intraperitoneaalselt manustatud tsüto-
toksilised ravimid kõrvaltoimeid kõhuõõne normaalsetes kudedes.  
Üheks võimaluseks ravimite ja kontrastainete efektiivsemaks muutmiseks ja 
kõrvalnähtude vähendamiseks on nende laadimine nanoosakestesse. Nanoosakes-
te abil on võimalik parandada ravimite lahustuvust, koeselektiivsust ja vabanemist 
sihtmärkkoes. Vähiravimite ja nanoosakeste koeselektiivsuse ja efektiivsuse 
parandamiseks saab neid suunata keemiliselt konjugeeritud afiinsusligandidega 
(nt. antikehad, peptiidid, aptameerid). Meie uurimisgrupp kasutab sellel eesmärgil 
vähiselektiivseid peptiide, näiteks iRGD vähkipenetreerivat peptiidi (TPP). Pärast 
seondumist rakupinna integriinidega läbib iRGD proteolüütilise lõikamise, mis 
aktiveerib seondumise teise vähirakkudel üleekspresseeritud valgu, NRP-1’ga ja 
käivitab rakuinternalisatsiooni raja. TT1 vähkipenetreeriva peptiidi retseptor on 
vähirakkude pinnal ekspresseeruv valk p32, mis normaalsetes rakkudes paikneb 
mitokondrites. TT1 peptiid kinnitub kasvajarakkude pinnal olevale p32’le ning 
käivitab seejärel NRP-1’st sõltuva rakkusisenemise protsessi.  
 Käesolev prekliiniline töö keskendub kõhuõõne vähkkasvajate (maovähk, 
soolevähk ja munasarjavähk) uute kuvamis- ja ravimeetodite väljatöötamisele 
kasutades erinevate koostisega nanoosakesi (nanoravimid) ning suunavaid 
vähiselektiivseid peptiide. Töös uuriti polümeeridel ja hõbedal põhinevate ning 
raudoksiidi sisaldavate nanoosakeste selektiivsust kasvajakoe suhtes peale 
kõhuõõnde süstimist. Katses kasutati erinevatel kõhuõõne kasvajarakkudel 
põhinevaid hiire loommudeleid. 
 
Uurimistöö eesmärgid 
1. Uurida TPP-NP spetsiifilisust sihtmärkvalkude suhtes rakuvabas kesk-
konnas ja rakukultuuris. 
2. Hinnata TPP-ga kaetud tsütotoksliste nanoosakeste rakku sisenemise 
võimet ja tsütotoksilisuse efekti. 
3. Määrata intraperitoneaalselt manustatud TPP-ga suunatud nanoosakeste 
biodistributsioon kõhuõõne kasvajatega hiirtes. 
4. Hinnata TPP-ga suunatud tsütotoksiliste nanoosakeste terapeutilist 
efektiivsust kõhuõõne kasvajatega hiirtes. 
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Materjal ja Metoodika 
Uurimistöös oli kasutusel kokku 5 erinevat kasvaja rakuliini, mis pärinevad kas 
inimeselt või hiirelt. Loomkatseteks kasutati atüümseid nude hiiri või Balb/c 
hiiri ning kõik loomkatseid olid kooskõlastatud Eesti Põllumajandusministee-
riumi vastava komisjoni poolt ning loomkatsetele oli väljastatud luba numbriga 
42. Värskete inimese soolevähi proovide saamine ja kasutamine oli kinnitatud 
Tartu Ülikooli Eetikakomisjoni poolt (luba numbriga 243/T27). Töös kasutati 
erinevaid tuumorispetsiifilisi peptiide (iRGD, LinTT1, RPARPAR, IP3), mis 
olid konjugeeritud nanoosakeste pinnale. Nanoosakestest kasutati polümer-
soome ning raud- ja hõbeosakesi. Nanoosakeste sünteesil kasutati erinevaid 
varem publitseeritud meetodeid; raudoksiidi osakeste sünteesil kasutati Fe-
soolasid ja kõrge molekulaarmassiga dekstraani, et saavutada usjalik-kuju ning 
polümersoomid saadi amfifiilsete kopolümeeride ja vee vastastikkusel toimel. 
Peptiidide lisamine nanoosakeste pinnale toimus kas NHS-PEG-maleimiid-
linkerit kasutades või läbi neutravidiin-biotiin interaktsiooni. Nanoosakeste 
iseloomustamiseks kasutati DLS tehnoloogiat ja transmissioonielektronmikro-
skoopiat. Selektiivsuse hindamisel rakuvabas süsteemis kasutati Ni-NTA mag-
neetilisi agaroosiosakesi millele seondati rekombinantsed p32 ja NRP-1 valgud. 
Fluoresentsmärgisega nanoosakeste seondumine valkudele tehti kindlaks 
kasutades flouresentsplaadilugejat. In vitro seondumiskatsed vähirakkudele 
viidi läbi kasutades voolutsütomeetriat ja konfokaalmikroskoopiat kasutades 
relevantseid primaarseid ja sekundaarseid antikehi. Tsütotoksilisuse hinda-
miseks kasutati MTT kolorimeetrilist meetodit ja xCELLigence® tehnoloogiat. 
In vivo koedistributsiooni katseteks indutseeriti hiirtes kõhuõõne kasvajad süsti-
des kasvajarakud otse kõhuõõnde ning hiljem teostati kasvajatest ja kontroll-
organitest valmistatud koelõikudel immuunohistokeemilised värvingud ja visua-
liseerimine kasutades konfokaalmikroskoopiat. Lisaks visualiseeriti raudoksiidi 
seondumist kasvajakoega in vivo MRT abil. Ekperimentaalteraapia hindamaks 
tsütotoksiliste nanoosakeste ja kullerpeptiidide efektiivsust viidi läbi mao-või 
soolevähiga hiiremudelitel süstides nanoosakesi otse kõhuõõnde ning katse 
lõpus hinnati kasvajakoe kaalu ning kasvajanoodulite arvu võrreldes kontroll-
osakestega süstitud hiirtega. 
 
 
Uurimistöö peamised tulemused ja järeldused  
1. LinTT1 ja RPARPAR peptiididega kaetud nanoosakesed seonduvad nende 
peptiidide teadaolevate retseptoritega (vastavalt p32 ja NRP-1) ning seda 
selektiivsust retseptori suhtes saab kasutada nanoosakeste suunamisel p32 ja 
NRP-1 ekspresseerivate rakkude pinnale. IP3 peptiid seondub hüaluroon-
happega in vitro. 
2. Rakku sisenenud linTT1-NW suunatakse mitokondritesse ning nad 
avaldavad tsütotoksililist toimet erinevatel IP kasvajarakkudel. TPP-PS´st 
vabanevad lastmolekulid tsütoplasmas ning avaldub tsütotoksline toime IP 
kasvajarakkudel. 
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3. TPP’ga konjugeerimine aitab kaasa nano-osakeste paremale akumulat-
sioonile kasvajakoes ja rakku sisenemisele. IP süstitud TPP-NP on võrreldes 
IV süstitud osakestega vähikoe suhtes selektiivsemad. IP manustatud TPP-
NP akumuleeruvad kasvajakoes nii otsese seondumise teel kasvajarakkudele 
kui ka kaudselt, vereringe kaudu.  
4. Polümersoomidel ja raudoksiidil põhinevate nanoosakeste suunamine TPP-
ga võimendab osakeste terapeutilist efektiivsust. 
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